WO2022244801A1 - Htlv-1核酸脂質粒子ワクチン - Google Patents
Htlv-1核酸脂質粒子ワクチン Download PDFInfo
- Publication number
- WO2022244801A1 WO2022244801A1 PCT/JP2022/020646 JP2022020646W WO2022244801A1 WO 2022244801 A1 WO2022244801 A1 WO 2022244801A1 JP 2022020646 W JP2022020646 W JP 2022020646W WO 2022244801 A1 WO2022244801 A1 WO 2022244801A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- htlv
- lipid
- lipids
- tax
- antigen
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 186
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 52
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 52
- -1 nucleic acid lipid Chemical class 0.000 title claims abstract description 37
- 229960005486 vaccine Drugs 0.000 title abstract description 8
- 150000002632 lipids Chemical class 0.000 claims abstract description 214
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims abstract description 169
- 108091007433 antigens Proteins 0.000 claims abstract description 120
- 102000036639 antigens Human genes 0.000 claims abstract description 120
- 239000000427 antigen Substances 0.000 claims abstract description 116
- 101800001271 Surface protein Proteins 0.000 claims abstract description 99
- 101800000385 Transmembrane protein Proteins 0.000 claims abstract description 99
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 44
- 208000015181 infectious disease Diseases 0.000 claims abstract description 23
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 103
- 239000000203 mixture Substances 0.000 claims description 70
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 68
- 125000003729 nucleotide group Chemical group 0.000 claims description 68
- 229920001223 polyethylene glycol Chemical class 0.000 claims description 64
- 229930182558 Sterol Chemical class 0.000 claims description 54
- 150000003432 sterols Chemical class 0.000 claims description 54
- 235000003702 sterols Nutrition 0.000 claims description 54
- 239000002773 nucleotide Substances 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 47
- 238000000338 in vitro Methods 0.000 claims description 43
- 125000002091 cationic group Chemical class 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 22
- 230000035772 mutation Effects 0.000 claims description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 16
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 16
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 16
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 12
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 12
- 208000006961 tropical spastic paraparesis Diseases 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 11
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 11
- 238000013519 translation Methods 0.000 claims description 11
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 10
- JFBCSFJKETUREV-LJAQVGFWSA-N 1,2-ditetradecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCC JFBCSFJKETUREV-LJAQVGFWSA-N 0.000 claims description 10
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 claims description 9
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 claims description 9
- 101710189104 Fibritin Proteins 0.000 claims description 9
- 229930185560 Pseudouridine Natural products 0.000 claims description 9
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 9
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 9
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims description 8
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000006384 oligomerization reaction Methods 0.000 claims description 7
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 229920001427 mPEG Polymers 0.000 claims description 6
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 5
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 5
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 4
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims description 3
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000002719 pyrimidine nucleotide Substances 0.000 claims description 3
- 150000003230 pyrimidines Chemical group 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 claims 3
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000001745 uvea Anatomy 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 108020004414 DNA Proteins 0.000 description 88
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 47
- 230000035897 transcription Effects 0.000 description 42
- 238000013518 transcription Methods 0.000 description 42
- 238000002360 preparation method Methods 0.000 description 37
- 238000005119 centrifugation Methods 0.000 description 31
- 239000000872 buffer Substances 0.000 description 30
- 239000006228 supernatant Substances 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 22
- 241000282693 Cercopithecidae Species 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 20
- 238000011534 incubation Methods 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 230000003248 secreting effect Effects 0.000 description 15
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 230000000903 blocking effect Effects 0.000 description 12
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 11
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 11
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 11
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 229960001456 adenosine triphosphate Drugs 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 11
- PCDQPRRSZKQHHS-XVFCMESISA-N CTP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-XVFCMESISA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 102000016911 Deoxyribonucleases Human genes 0.000 description 9
- 108010053770 Deoxyribonucleases Proteins 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 101710137500 T7 RNA polymerase Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000012228 culture supernatant Substances 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 206010007269 Carcinogenicity Diseases 0.000 description 8
- 231100000260 carcinogenicity Toxicity 0.000 description 8
- 230000007670 carcinogenicity Effects 0.000 description 8
- 230000005758 transcription activity Effects 0.000 description 8
- 230000024932 T cell mediated immunity Effects 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 101150077194 CAP1 gene Proteins 0.000 description 6
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 238000007069 methylation reaction Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 5
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 101100438378 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-1 gene Proteins 0.000 description 4
- OLRONOIBERDKRE-XUTVFYLZSA-N [[(2r,3s,4r,5s)-3,4-dihydroxy-5-(1-methyl-2,4-dioxopyrimidin-5-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 OLRONOIBERDKRE-XUTVFYLZSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000012089 stop solution Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000011735 C3H mouse Methods 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 108010038751 tax Gene Products Proteins 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 101800001779 2'-O-methyltransferase Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- SAQBXWDJOZMALC-BRSPMRJASA-N [(Z,7R)-18-[3-(dimethylamino)propoxycarbonyloxy]octacos-9-en-7-yl] acetate Chemical compound C(C)(=O)O[C@H](CCCCCC)C\C=C/CCCCCCCC(CCCCCCCCCC)OC(=O)OCCCN(C)C SAQBXWDJOZMALC-BRSPMRJASA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YEPAFLHOTODYGA-UHFFFAOYSA-N 3-(dimethylamino)propyl hydrogen carbonate Chemical compound CN(C)CCCOC(O)=O YEPAFLHOTODYGA-UHFFFAOYSA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical group C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150014715 CAP2 gene Proteins 0.000 description 1
- VPIFLLYNZMFSSO-JLPSZBEASA-N CCCCCC[C@H](C/C=C\CCCCCCCC(CCCCCCC/C=C\C[C@@H](CCCCCC)CC(O)=O)OC(OCCCN(C)C)=O)CC(O)=O Chemical compound CCCCCC[C@H](C/C=C\CCCCCCCC(CCCCCCC/C=C\C[C@@H](CCCCCC)CC(O)=O)OC(OCCCN(C)C)=O)CC(O)=O VPIFLLYNZMFSSO-JLPSZBEASA-N 0.000 description 1
- 229940022962 COVID-19 vaccine Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- PCDQPRRSZKQHHS-UHFFFAOYSA-N Cytidine 5'-triphosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100326803 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-2 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241001662443 Phemeranthus parviflorus Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710132632 Protein C4 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710087759 Sliding-clamp-loader small subunit Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Chemical group O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Chemical group OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to nucleic acid lipid particle vaccines encapsulating HTLV-1 mRNA.
- HTLV-1 Human T-cell leukemia virus type 1
- Non-Patent Document 1 Human T-cell leukemia virus type 1
- ATL adult T-cell leukemia
- no standard treatment has been established that contributes to satisfactory therapeutic effects for ATL. For example, combination chemotherapy, one of the standard treatments, has less than 10% long-term survivors.
- Non-Patent Document 2 graft versus leukemia effect
- Tax has the ability to activate NF-kB and is a protein essential for HTLV-1 replication (Non-Patent Document 4). Excessive Tax-mediated NF-kB activation is also observed in HTLV-1-infected cells and ATL cells. (Non-Patent Document 5, Non-Patent Document 6). In addition, in Non-Patent Document 7, amino acids important for NF-kB activation of Tax have been identified, and using Tax mutants in which point mutations are inserted in these amino acids, the mechanism of NF-kB activation by Tax The ordinal has been analyzed (8, 9). However, there are no examples of effective vaccines to prevent or treat HTLV-1 using Tax or Tax mutants.
- HTLV-1 infection targets the HTLV-1 envelope protein gp46. It has been shown that it is neutralized by an anti-gp46 antibody that is capable of producing anti-gp46 antibodies (Non-Patent Document 10). It has also been suggested that neutralizing anti-gp46 antibodies may prevent vertical infection in vertical infection models using rats. However, there are no examples of effective vaccines to prevent or treat HTLV-1 using gp46.
- LNP-mRNA LNP formulations in which mRNA encoding an antigen is encapsulated in lipid nanoparticles
- SARS-CoV-2 vaccine Non-Patent Document 11
- influenza vaccine Patent Document 1
- the purpose of the present invention is to provide a vaccine for preventing and/or treating infection by human T-cell Leukemia virus type 1 (Human T-cell Leukemia Virus type 1: HTLV-1).
- HTLV-1 mRNA-encapsulated nucleic acid lipid particles can be applied to the treatment and prevention of adult T-cell leukemia, and have completed the present invention.
- LNP-mRNA-HTLV-1 encapsulating mRNA expressing HTLV-1 Tax and gp46 was prepared, and in mice and monkeys to which LNP-mRNA-HTLV-1 was administered, HTLV-1 Tax and induced antibody production and CTL against gp46, as well as neutralizing activity that inhibits proliferation of HTLV-1 infected cells.
- the gist of the present invention is as follows.
- Said particle comprising a lipid, or a pharmaceutically acceptable salt thereof.
- R 1 and R 2 independently represent a C 1 -C 3 alkyl group
- L 1 represents a C 17 -C 19 alkenyl group optionally having one or more C 2 -C 4 alkanoyloxy groups
- L 2 is a C 10 -C 19 alkyl group optionally having one or more C 2 -C 4 alkanoyloxy groups, or optionally having one or more C 2 -C 4 alkanoyloxy groups exhibiting good C 10 -C 19 alkenyl groups
- p is 3 or 4
- the particles according to (1), wherein both R 1 and R 2 in general formula (Ia) are methyl groups.
- L 1 in general formula (Ia) is a C 17 -C 19 alkenyl group optionally having one or more acetoxy groups; particle.
- L 2 in general formula (Ia) is a C 10 -C 12 alkyl group optionally having one or more acetoxy groups, or C optionally having one or more acetoxy groups
- L 2 in general formula (Ia) is a C 10 -C 12 alkyl group optionally having one or more acetoxy groups, or C optionally having one or more acetoxy groups A particle according to any one of (1) to (4), which is a 17 -C 19 alkenyl group.
- L 1 in general formula (Ia) is (R)-11-acetyloxy-cis-8-heptadecenyl group, cis-8-heptadecenyl group, or (8Z,11Z)-heptadecadienyl group; A particle according to any one of (1) to (6).
- L 2 in general formula (Ia) is a decyl group, cis-7-decenyl group, dodecyl group, or (R)-11-acetyloxy-cis-8-heptadecenyl group, (1)- The particles according to any one of (7).
- the cationic lipid has the following structural formula: The particles according to (1) represented by. (10) the cationic lipid has the following structural formula: The particles according to (1) represented by. (11) the cationic lipid has the following structural formula: The particles according to (1) represented by. (12) The particles of (9) or (10), wherein the lipid further comprises amphipathic lipids, sterols and PEG lipids.
- the amphipathic lipid is at least one selected from the group consisting of distearoylphosphatidylcholine, dioleoylphosphatidylcholine and dioleoylphosphatidylethanolamine.
- the amphiphilic lipid is at least one selected from the group consisting of distearoylphosphatidylcholine, dioleoylphosphatidylcholine and dioleoylphosphatidylethanolamine.
- PEG lipid is 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol and/or N-[methoxy poly(ethylene glycol) 2000]carbamoyl]-1,2-dimyristyloxypropyl-3-amine
- the lipid composition of amphipathic lipids, sterols, cationic lipids, and PEG lipids is, in molar amounts, 5-25% amphipathic lipids, 10-55% sterols, and cationic lipids.
- the lipid composition of amphipathic lipids, sterols, cationic lipids, and PEG lipids is, in molar amounts, 5-15% amphipathic lipids, 35-50% sterols, and cationic lipids.
- the lipid composition of amphiphilic lipids, sterols, cationic lipids, and PEG lipids, in molar amounts, is 10-25% amphipathic lipids, 10-50% sterols, and cationic lipids.
- HTLV-1 human T-cell leukemia virus type 1
- HTLV-1 a fusion protein with an oligomerization domain.
- 32) The particle of (31), wherein the oligomerization domain is fibritin.
- 33) The particle of (31) or (32), wherein the gp46 antigen of human T-cell leukemia virus type 1 (HTLV-1) consists of an amino acid sequence having at least 95% identity with the amino acid sequence of SEQ ID NO:14.
- the tax antigen of human T-cell leukemia virus type 1 has at least one mutation selected from the group consisting of T130A, L131S, L319R and L320S in the amino acid sequence of SEQ ID NO: 11; and having at least 95% identity with the amino acid sequence of SEQ ID NO: 11 when comparing the amino acid sequences other than the mutated amino acid.
- the tax antigen of human T-cell leukemia virus type 1 has mutations of T130A, L131S, L319R and L320S with respect to the amino acid sequence of SEQ ID NO: 11, and the amino acid sequence other than the mutated amino acids; (34) consisting of an amino acid sequence having at least 95% identity with the amino acid sequence of SEQ ID NO: 11 when compared to (36)
- the nucleic acid capable of expressing human T-cell leukemia virus type 1 (HTLV-1) gp46 antigen or Tax antigen is a cap structure (Cap), 5' untranslated region (5'-UTR) gp46 antigen or
- the sequence of the nucleic acid capable of expressing the gp46 antigen of human T-cell leukemia virus type 1 consists of a nucleotide sequence having at least 90% identity with the sequence of SEQ ID NO: 17 or 18 ( 38).
- the sequence of the nucleic acid capable of expressing the Tax antigen of human T-cell leukemia virus type 1 consists of a nucleotide sequence having at least 90% identity with the sequence of SEQ ID NO: 20; (38) The particles described in .
- nucleic acid comprises at least one modified nucleotide.
- modified nucleotide comprises at least one pyrimidine nucleotide substituted at position 5 and/or pseudouridine optionally substituted at position 1.
- modified nucleotide comprises at least one selected from the group consisting of 5-methylcytidine, 5-methoxyuridine, 5-methyluridine, pseudouridine, and 1-alkylpseudouridine.
- a composition comprising the particles according to any one of (1) to (45).
- HTLV-1 human T-cell leukemia virus type 1
- ATLL adult T-cell leukemia/lymphoma
- HAM HTLV-1-associated myelopathy
- HU HTLV-1 uveitis
- gp46 antigen or Tax antigen of human T-cell leukemia virus type 1 comprising introducing the composition according to any one of (47) to (50) into a cell how to let (54) human T-cell leukemia virus type 1 (HTLV-1) gp46 antigen or Tax antigen in vivo, comprising administering the composition according to any one of (47) to (51) to a mammal; How to express.
- a method for preventing and/or treating human T-cell leukemia virus type 1 (HTLV-1) infection comprising administering the composition according to any one of (49) to (52) to a mammal.
- HTLV-1 human T-cell leukemia virus type 1
- ATLL Adult T-cell leukemia/lymphoma
- HAM HTLV-1 associated myelopathy
- HTLV-1 grape comprising administering the composition of any of (49) to (52) to a mammal
- Tax antigen A human T-cell leukemia virus type 1 (HTLV-1) Tax antigen, which is a peptide obtained by fusing a Tax antigen having a mutation that reduces or eliminates carcinogenicity with a signal peptide.
- Tax antigen has at least one mutation selected from the group consisting of T130A, L131S, L319R and L320S with respect to the amino acid sequence of SEQ ID NO: 11, and amino acid sequences other than the mutated amino acid were compared.
- the nucleic acid capable of expressing the human T-cell leukemia virus type 1 (HTLV-1) gp46 antigen or Tax antigen comprises a cap structure (Cap), a 5' untranslated region (5'-UTR), a gp46 antigen Or the particle according to any one of (31) to (37), which is an mRNA comprising a Tax antigen translation region and a 3′-untranslated region (3′-UTR).
- (62) a configuration consisting of a cap structure (Cap), a 5′ untranslated region (5′-UTR), a gp46 antigen or Tax antigen translated region, and a 3′ untranslated region (3′-UTR) of SEQ ID NO: 17
- a particle according to (61) which is a nucleotide sequence having at least 90% identity with sequences 1 to 1141 or sequences 1 to 1222 of SEQ ID NO:18.
- (63) a configuration consisting of a cap structure (Cap), a 5′ untranslated region (5′-UTR), a gp46 antigen or Tax antigen translated region, and a 3′ untranslated region (3′-UTR) of SEQ ID NO: 20
- Cap cap structure
- 5′-UTR 5′ untranslated region
- gp46 antigen or Tax antigen translated region 5′-UTR
- 3′-UTR 3′ untranslated region
- the present invention makes it possible to prevent and/or treat infection with human T-cell leukemia virus type 1 (HTLV-1).
- HTLV-1 human T-cell leukemia virus type 1
- the present invention makes it possible to prevent and/or treat diseases caused by HTLV-1 infection.
- the particles of the present invention have excellent properties in terms of metabolic stability, in vitro activity, in vivo activity, rapid onset of efficacy, duration of efficacy, physical stability, drug interaction, safety, and the like. and is useful as a medicament for treating or preventing the above diseases.
- FIG. 2 shows HIV-1 LTR transcription activity (A) and HTLV-1 LTR transcription activity (B) by Tax wild-type, Tax mutant, and secretory Tax mutant.
- pHIV-1 LTR indicates the HIV-1 LTR reporter plasmid-administered group
- pHTLV-1 LTR the HTLV-1 LTR reporter plasmid-administered group
- Empty indicates the negative control group pcDNA3.1+vector.
- vertical bars indicate mean values
- error bars indicate SD.
- White circles on the bar graph indicate individual data for Triplicate.
- Tax WT Tax wild type
- Tax Mut Tax mutant
- Sec-Tax Mut secretory Tax mutant.
- FIG. 10 shows Tax-specific CTL induction levels and blood anti-Tax antibody titers in C3H mice to which the lipid particles of Example 12 were administered.
- FIG. 2A shows Tax-specific CTL induction levels
- FIG. 2B shows blood anti-Tax antibody titers.
- FIG. 4 shows monkey blood anti-gp46 antibody titers and blood anti-Tax antibody titers.
- FIG. 3A shows blood anti-gp46-specific antibody titers
- FIG. 3B shows blood anti-Tax antibody titers. 4 animals per group. 0W, 2W, 4W, or 6W are before administration, 2 weeks after the first administration, 4 weeks (2 weeks after the 2nd administration), and 6 weeks (2 weeks after the 3rd administration), respectively.
- FIG. 1 shows gp46-specific and Tax-specific cellular immune responses. 4 animals per group. Vertical bars indicate mean values, error bars indicate SD. White circles on bar graphs indicate individual data.
- FIG. 1 shows anti-HTLV-1 neutralizing activity in monkey blood. Assay negative controls represent results with no antibody treatment and assay positive controls represent results with known HTLV-1 neutralizing antibody treatment. 4 animals per group. #736, #741, #743, and #737 indicate individual monkey IDs of the negative control group, and #745, #742, #740, and #735 indicate individual monkey IDs of the mixed formulation administration groups of Examples 5 and 6. indicate. Arrows indicate syncytial formation. FIG.
- FIG. 4 shows blood anti-gp46 antibody titers in C57BL/6 mice.
- FIG. 4 shows gp46-specific and Tax-specific cellular immune responses in C57BL/6 mice.
- FIG. 7A shows IFN- ⁇ production levels and
- FIG. 7B shows IL-2 production levels.
- FIG. 4 shows gp46 and Tax protein expression levels in CHO-S cells treated with lipid particles of Examples 9-12.
- FIG. 8A shows expression levels in cell lysates and FIG. 8B shows expression levels in culture supernatants.
- FIG. 1 shows the nucleotide sequence (SEQ ID NO: 1) of template plasmid DNA for HTLV-I SU gp46 IVT.
- FIG. 1 shows the nucleotide sequence (SEQ ID NO: 1) of template plasmid DNA for HTLV-I SU gp46 IVT.
- FIG. 1 shows the nucleotide sequence (SEQ ID NO: 1) of template plasmid DNA for HTLV-I
- FIG. 2 shows the nucleotide sequences of the sense primer (SEQ ID NO: 2) and antisense primer (SEQ ID NO: 3).
- FIG. 4 shows the nucleotide sequence (SEQ ID NO: 4) of template DNA for in vitro transcription (IVT) of SU gp46.
- FIG. 5 shows the nucleotide sequence (SEQ ID NO: 5) of template plasmid DNA for HTLV-I gp46-Fib IVT.
- FIG. 6 shows the nucleotide sequence (SEQ ID NO: 6) of template DNA for in vitro transcription (IVT) of gp46-Fib.
- FIG. 7 shows the nucleotide sequence (SEQ ID NO: 7) of template plasmid DNA for HTLV-I dgp62-Fib IVT.
- FIG. 8 shows the nucleotide sequence (SEQ ID NO: 8) of template DNA for in vitro transcription (IVT) of dgp62-Fib.
- FIG. 9 shows the nucleotide sequence (SEQ ID NO: 9) of template plasmid DNA for HTLV-I sec Tax mutant IVT.
- FIG. 10 shows the nucleotide sequence (SEQ ID NO: 10) of the template DNA for in vitro transcription (IVT) of the sec Tax mutant.
- FIG. 11 shows the amino acid sequence of Tax wild-type (SEQ ID NO: 11).
- FIG. 12 shows the amino acid sequence (SEQ ID NO: 12) of Tax mutant (T130A/L131S/L319R/L320S).
- FIG. 13 shows the amino acid sequence (SEQ ID NO: 13) of a secretory Tax mutant (T130A/L131S/L319R/L320S).
- FIG. 1 shows the amino acid sequence of gp46 (SEQ ID NO: 14).
- FIG. 2 shows the amino acid sequence of gp46-Fib (SEQ ID NO: 15).
- FIG. 2 shows the amino acid sequence of dgp62-Fib (SEQ ID NO: 16).
- FIG. 4 shows the nucleotide sequence of SU gp46 mRNA (SEQ ID NO: 17).
- FIG. 4 shows the nucleotide sequence of gp46-Fib mRNA (SEQ ID NO: 18).
- Fig. 2 shows the nucleotide sequence of dgp62-Fib mRNA (SEQ ID NO: 19).
- FIG. 2 shows the nucleotide sequence of sec Tax mutant mRNA (SEQ ID NO: 20).
- FIG. 4 shows gp46 protein expression levels in CHO-S cells treated with Examples 30-34. A dotted line indicates the OD value of Buffer, which is a negative control.
- FIG. 2 shows the nucleotide sequence polyA95 (SEQ ID NO: 21) of the template DNA of gp46-Fib.
- FIG. 2 shows the nucleotide sequence polyA80 (SEQ ID NO: 22) of the template DNA of gp46-Fib.
- FIG. 4 shows the nucleotide sequence polyA60 (SEQ ID NO: 23) of the template DNA of gp46-Fib.
- FIG. 4 shows the nucleotide sequence polyA40 (SEQ ID NO: 24) of the template DNA of gp46-Fib.
- FIG. 4 shows the nucleotide sequence polyA20 (SEQ ID NO: 25) of the template DNA of gp46-Fib.
- Fig. 2 shows the nucleotide sequence polyA95 (SEQ ID NO: 26) of the template DNA of the sec Tax mutant.
- FIG. 2 shows the nucleotide sequence polyA80 (SEQ ID NO: 27) of the template DNA of the sec Tax mutant.
- FIG. 2 shows the nucleotide sequence polyA60 (SEQ ID NO: 28) of the template DNA of the sec Tax mutant.
- FIG. 10 shows the nucleotide sequence polyA40 (SEQ ID NO: 29) of the template DNA of the sec Tax mutant.
- FIG. 3 shows the nucleotide sequence polyA20 (SEQ ID NO: 30) of the template DNA of the sec Tax mutant.
- Fig. 3 shows the gp46-Fib mRNA sequence polyA95 (SEQ ID NO: 31).
- Fig. 3 shows the gp46-Fib mRNA sequence polyA80 (SEQ ID NO: 32).
- FIG. 3 shows the gp46-Fib mRNA sequence polyA60 (SEQ ID NO: 33).
- Fig. 2 shows the gp46-Fib mRNA sequence polyA40 (SEQ ID NO: 34).
- FIG. 3 shows the gp46-Fib mRNA sequence polyA20 (SEQ ID NO: 35).
- Fig. 3 shows the sec Tax mutant mRNA sequence polyA95 (SEQ ID NO: 36).
- Fig. 3 shows the sec Tax mutant mRNA sequence polyA80 (SEQ ID NO: 37).
- Fig. 3 shows the sec Tax mutant mRNA sequence polyA60 (SEQ ID NO: 38).
- Fig. 3 shows the sec Tax mutant mRNA sequence polyA40 (SEQ ID NO: 39).
- Fig. 2 shows the sec Tax mutant mRNA sequence polyA20 (SEQ ID NO: 40).
- the present invention provides lipid particles encapsulating a nucleic acid capable of expressing HTLV-1 gp46 antigen or Tax antigen, wherein the lipid is a cationic lipid represented by general formula (Ia), or a pharmaceutically acceptable providing said particles comprising a salt comprising:
- R 1 and R 2 independently represent a C 1 -C 3 alkyl group
- L 1 represents a C 17 -C 19 alkenyl group optionally having one or more C 2 -C 4 alkanoyloxy groups
- L 2 is a C 10 -C 19 alkyl group optionally having one or more C 2 -C 4 alkanoyloxy groups, or optionally having one or more C 2 -C 4 alkanoyloxy groups exhibiting good C 10 -C 19 alkenyl groups
- p is 3 or 4;
- R 1 and R 2 in general formula (Ia) independently represent a C 1 -C 3 alkyl group, but both are preferably methyl groups.
- p in general formula (Ia) is 3 or 4, preferably 3.
- L 1 in general formula (Ia) represents a C 17 -C 19 alkenyl group optionally having one or more C 2 -C 4 alkanoyloxy groups, preferably one or more acetoxy groups. It is a C 17 -C 19 alkenyl group which may have one. Specific examples of L 1 include (R)-11-acetyloxy-cis-8-heptadecenyl group, cis-8-heptadecenyl group, or (8Z,11Z)-heptadecadienyl group. can.
- L 2 in general formula (Ia) is a C 10 -C 19 alkyl group optionally having one or more C 2 -C 4 alkanoyloxy groups, or one or more C 2 -C 4 alkanoyloxy groups; represents a C 10 -C 19 alkenyl group which may have a plurality of acetoxy groups, preferably a C 10 -C 12 alkyl group which may have one or a plurality of acetoxy groups, or one or a plurality of acetoxy groups; It is a C 10 -C 19 alkenyl group which may have one.
- L 2 in general formula (Ia) is a C 10 -C 12 alkyl group optionally having one or more acetoxy groups, or C optionally having one or more acetoxy groups It is also preferred to be a 17 - C19 alkenyl group.
- Specific examples of L2 include a decyl group, cis - 7-decenyl group, dodecyl group, or (R)-11-acetyloxy-cis-8-heptadecenyl group.
- the cationic lipid which is a component constituting the particles of the present invention, has the following structural formula: (7R,9Z,26Z,29R)-18-( ⁇ [3-(dimethylamino)propoxy]carbonyl ⁇ oxy)pentatriacont-9,26-diene-7,29-diyl diacetic acid represented, respectively, 3-dimethylaminopropyl (9Z,12Z)-octacosa-19,22-dien-11-yl carbonate, (7R,9Z)-18-( ⁇ [3-(dimethylamino)propyloxy]carbonyl ⁇ oxy)octacosa acetate -9-en-7-yl can be exemplified.
- the cationic lipid represented by general formula (Ia) may be one type of compound or a combination of two or more types of compounds.
- the lipids of the present invention may further include amphiphilic lipids, sterols and PEG lipids.
- Amphiphilic lipids are lipids that have affinity for both polar and non-polar solvents. can be exemplified. Distearoylphosphatidylcholine and/or dioleoylphosphatidylethanolamine are preferred as the amphiphilic lipid used in the particles of the present invention, and distearoylphosphatidylcholine is more preferred.
- Sterols are sterols having a hydroxy group, and specific examples include cholesterol.
- PEG lipids are PEG-modified lipids, specifically 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol and/or N-[methoxypoly(ethylene glycol)2000]carbamoyl]-1,2 -dimyristyloxypropyl-3-amine, combinations thereof, etc., preferably 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol.
- the average molecular weight of the PEG lipid is not particularly limited, but is, for example, 1000-5000, preferably 1500-3000, more preferably 1800-2200.
- Lipid compositions of amphiphilic lipids, sterols, cationic lipids, and PEG lipids are not particularly limited, but are, for example, 5-25% amphipathic lipids and 10 sterols in molar amounts.
- ⁇ 55% cationic lipids, 1-5% PEG lipids, and the lipid composition of amphiphilic lipids, sterols, cationic lipids, and PEG lipids is, in molar amounts, amphiphilic preferably 10-25% lipids, 10-55% sterols, 40-65% cationic lipids, and 1-5% PEG lipids, amphipathic lipids, sterols, cationic lipids, and The lipid composition of the PEG lipids is 10-22.5% amphipathic lipids, 15-55% sterols, 40-65% cationic lipids, and 1-5% PEG lipids in molar amounts. is more preferable.
- the proportion of PEG lipid in the lipid composition is 1-3%, even more preferably 1-2%, even more preferably 1.2-2% in molar amount. , is even more preferably 1.25 to 2%, even more preferably 1.3 to 2%, and particularly preferably 1.5 to 2%.
- the ratio of the total lipid weight to the nucleic acid weight in the lipid composition is not particularly limited, but may be 15 to 30, preferably 15 to 25, more preferably 15 to 22.5, 17 0.5 to 22.5 is even more preferred.
- the lipid composition of amphipathic lipids, sterols, cationic lipids, and PEG lipids is particularly limited.
- amphipathic lipids are 15% or less
- sterols are 20-55%
- cationic lipids are 40-65%
- PEG lipids are 1-5%
- the lipid composition of the PEG lipids, in molar amounts is 5-15% amphipathic lipids, 35-50% sterols, 40-55% cationic lipids, and 1-3% PEG lipids.
- the lipid composition of amphipathic lipids, sterols, cationic lipids, and PEG lipids is 10-15% amphipathic lipids, 35-45% sterols, cationic Even more preferably, 40-50% lipids and 1-2.5% PEG lipids, wherein the lipid composition of amphipathic lipids, sterols, cationic lipids, and PEG lipids is, in molar amounts, Even more preferably 10-15% vehicle lipids, 35-45% sterols, 40-50% cationic lipids and 1-2% PEG lipids.
- the PEG lipid in the above lipid composition is 1.2-2%, even more preferably 1.25-2%, even more preferably 1.3-2%, 1 0.5 to 2% is even more preferred.
- the ratio of the total lipid weight to the nucleic acid weight is not particularly limited, but may be 15 to 30, preferably 15 to 25, more preferably 15 to 22.5, and 17.5 to 17.5. 22.5 is even more preferred.
- the lipid composition of the cationic lipid and the PEG lipid is not particularly limited. 40-65%, 1-5% PEG lipids, 10-25% amphipathic lipids, 10-50% sterols, 40-65% cationic lipids, 1-5% PEG lipids.
- the lipid composition of amphipathic lipid, sterols, cationic lipid, and PEG lipid is 10-25% amphipathic lipid, 10-50% sterols, cationic More preferably 40-65% lipid and 1-3% PEG lipid, the lipid composition of amphipathic lipids, sterols, cationic lipids and PEG lipids, in molar amounts, amphipathic lipids is 10-25%, sterols are 10-45%, cationic lipids are 42.5-65%, PEG lipids are 1-2.5%, amphipathic lipids, sterols, Lipid composition of cationic lipids and PEG lipids, in molar amounts, is 15-22.5% amphipathic lipids, 15-40% sterols, 45-65% cationic lipids, and 1 PEG lipid.
- the lipid composition of amphiphilic lipids, sterols, cationic lipids, and PEG lipids is 17.5-22.5% amphipathic lipids, in molar amounts, Even more preferably 15-40% sterols, 45-65% cationic lipids and 1-2% PEG lipids. More preferably, the PEG lipid in the above lipid composition is 1.2-2%, even more preferably 1.25-2%, even more preferably 1.3-2%, 1 0.5 to 2% is even more preferred.
- the ratio of the total lipid weight to the nucleic acid weight in the lipid composition is not particularly limited, it is preferably 15 to 30, more preferably 15 to 25, even more preferably 15 to 22.5, and 17 0.5 to 22.5 is even more preferred.
- Specific lipid combinations in the present invention include distearoylphosphatidylcholine, dioleoylphosphatidylcholine, or dioleoylphosphatidylethanolamine as amphipathic lipids, cholesterol as sterols, and diacetic acid (7R, 9Z, 26Z,29R)-18-( ⁇ [3-(dimethylamino)propoxy]carbonyl ⁇ oxy)pentatriacont-9,26-diene-7,29-diyl, 3-dimethylaminopropyl carbonate (9Z,12Z)- Octacosa-19,22-dien-11-yl or (7R,9Z)-18-( ⁇ [3-(dimethylamino)propyloxy]carbonyl ⁇ oxy)octacosa-9-en-7-yl acetate, PEG lipid 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol or N-[methoxypoly(ethylene glyco
- distearoylphosphatidylcholine or dioleoylphosphatidylethanolamine as amphiphilic lipids
- cholesterol as sterols
- a lipid combination using 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol as the 9-en-7-yl, PEG lipid is preferred.
- distearoylphosphatidylcholine as an amphiphilic lipid
- cholesterol as a sterol
- diacetic acid (7R,9Z,26Z,29R)-18-( ⁇ [3- (dimethylamino)propoxy]carbonyl ⁇ oxy)pentatriacont-9,26-diene-7,29-diyl, or (7R,9Z)-18-( ⁇ [3-(dimethylamino)propyloxy]carbonyl ⁇ acetate) oxy)octacosa-9-en-7-yl, 1,2-dimyristoyl-sn-glycerol, methoxypolyethylene glycol as PEG lipid.
- the nucleic acid encapsulated in the lipid particles is capable of expressing the HTLV-1 gp46 antigen or Tax antigen.
- the amino acid sequence of the HTLV-1 gp46 antigen is shown in SEQ ID NO: 14.
- the nucleic acid encapsulated in the lipid particles consists of an amino acid sequence having at least 95%, preferably 96%, more preferably 97%, more preferably 98% identity with the amino acid sequence of SEQ ID NO: 14. It may encode the gp46 antigen.
- the gp46 antigen may be a fusion protein with an oligomerization domain.
- An oligomerization domain is a protein that multimerizes a fused protein, such as fibritin from the T4 bacteriophage.
- the foldon domain which is the trimerization domain of fibritin, can be used.
- the amino acid sequence of the HTLV-1 gp46-fibritin fusion protein is shown in SEQ ID NO:15.
- the 313rd to 339th amino acid sequence of the amino acid sequence of SEQ ID NO: 15 is the amino acid sequence of fibritin.
- the oligomerization domain may be located at the C-terminus or N-terminus of the gp46 antigen.
- the amino acid sequence of the HTLV-1 wild-type Tax antigen is shown in SEQ ID NO: 11.
- the nucleic acid encapsulated in the lipid particles encodes the HTLV-1 Tax antigen consisting of an amino acid sequence having at least 95%, preferably 96%, more preferably 97% identity with the amino acid sequence of SEQ ID NO: 11.
- the wild-type Tax antigen has HTLV-1 LTR transcriptional activity and is carcinogenic, it is necessary to reduce or eliminate the toxicity of carcinogenicity to living organisms.
- a Tax antigen having mutations that reduce or eliminate carcinogenicity may be used.
- the extracellular secretion of Tax reduces the carcinogenicity of cells, it may be a fusion protein with a signal peptide.
- Mutations that reduce or eliminate carcinogenicity include T130A, L131S, L319R and L320S.
- T130A and L131S are HIV-1 LTR and HTLV-1 transcriptionally inactive mutations
- L319R and L320S are HTLV-1 transcriptionally deficient mutations. It suffices to have at least one of these mutations, preferably two, more preferably three, and particularly preferably four.
- SEQ ID NO: 12 shows the amino acid sequence of the mutant Tax antigen having the above four mutations.
- Signal peptides for extracellular secretion of Tax antigens include IgE secretory signal peptides.
- a signal peptide is preferably fused to the N-terminal side of the Tax antigen.
- SEQ ID NO: 13 shows the amino acid sequence of the fusion protein between the signal peptide and the mutant Tax antigen having the above four mutations.
- the 1st to 18th amino acid sequence of the amino acid sequence of SEQ ID NO: 13 is the amino acid sequence of the IgE secretory signal peptide.
- the present invention provides an IgE secretion signal for a Tax variant obtained by fusing a signal peptide to a Tax antigen having at least one, preferably two, more preferably three, and particularly preferably four of the above four amino acid mutations.
- includes peptides that are secretory Tax variants with the addition of The peptide is a Tax antigen of human T-cell leukemia virus type 1 (HTLV-1), and is a peptide obtained by fusing a Tax antigen having a mutation that reduces or eliminates carcinogenicity with a signal peptide. Mutations that reduce or eliminate carcinogenicity include T130A, L131S, L319R and L320S.
- the Tax antigen has at least one mutation selected from the group consisting of T130A, L131S, L319R and L320S with respect to the amino acid sequence of SEQ ID NO: 11, and an amino acid sequence other than the mutated amino acid and peptides consisting of an amino acid sequence having at least 95%, preferably 96%, more preferably 97% identity with the amino acid sequence of SEQ ID NO: 11 when compared to .
- Signal peptides for extracellular secretion of Tax antigens include IgE secretory signal peptides.
- a signal peptide is preferably fused to the N-terminal side of the Tax antigen.
- the 1st to 18th amino acid sequence of the amino acid sequence of SEQ ID NO: 13 is the amino acid sequence of the IgE secretory signal peptide. That is, examples of the above peptides include peptides in which the signal peptide consists of the amino acid sequence of 1st to 18th amino acids of SEQ ID NO:13.
- the nucleic acid encapsulated in the lipid particles may be capable of expressing a protein in which the gp46 antigen of HTLV-1 and the Tax antigen are bound by a linker.
- the linker consists of an amino acid sequence containing a sequence that is cleaved by a protease, for example, a linker containing an amino acid sequence that is recognized and cleaved by the protease Furin.
- the protease cleavage sequence may be any sequence that can be cleaved by the Furin protein, and is represented, for example, by RXK/RR (R for arginine, K for lysine, and X for any amino acid). (J. Biol. Chem. 1992, 267, 16396; J. Biol. Chem. 1991, 266, 12127).
- the identity of an amino acid sequence is a quantification of the percentage of amino acid identity with respect to the full-length sequence, with amino acids for which the corresponding amino acids are completely identical as the same amino acid. Sequence identity in the present invention is calculated using sequence analysis software GENETYX-SV/RC (manufactured by Genetics Inc.), and this algorithm is commonly used in the art.
- the amino acids encoded by the nucleic acids to be encapsulated in the lipid particles of the present invention are subject to amino acid mutation (substitution), deletion, insertion and/or addition as long as they retain a certain degree of identity with SEQ ID NOS: 11-16. can be
- the amino acid encoded by the nucleic acid encapsulated in the lipid particle of the present invention retains the above-described sequence identity, and has several positions (preferably 5 positions or less, more preferably 3 or 2 positions in the amino acid sequences of SEQ ID NOs: 11 to 16). or 1 position), several (preferably 10 or less, more preferably 7 or less, more preferably 5, 4, 3, 2 or 1) amino acids per position are substituted, deleted, inserted and / Or it may be added.
- Nucleic acids capable of expressing HTLV-1 gp46 antigen or Tax antigen include cap structure (Cap), 5′ untranslated region (5′-UTR), gp46 or Tax translated region, 3′ untranslated region (3 '-UTR) and a poly A tail (polyA). It may also have a KOZAK sequence on the 5' side of the translational region of gp46 or Tax.
- the cap structure (Cap) is present at the 5' end of many eukaryotic mRNAs and is a site with a 7-methylguanosine structure.
- Cap structures include, for example, cap0, cap1, cap2, cap structures when ARCA (Anti-Reverse Cap Analog) is used, and the cap structures are represented by the following structural formulas.
- Base indicates any unmodified or modified nucleobase
- RNA indicates any polynucleotide.
- the cap structure of the mRNA of the present invention is preferably cap0 or cap1, more preferably cap1.
- the 5'-untranslated region (5'-UTR) sequence for example, a sequence containing the 5'-untranslated region of the human ⁇ -globin gene can be used.
- the sequence of the 5' untranslated region of the human ⁇ -globin gene is the sequence of nucleotide numbers 15-64 in the sequence of SEQ ID NO:17.
- the sequence of the gp46 translational region is a sequence capable of expressing all or part of the amino acid sequence of the gp46 antigen, and may include a start codon and/or a stop codon. Sequence numbered 71-1009.
- sequence of the translation region of gp46 and the sequence of fibritin may be ligated, for example, the sequence of nucleotide numbers 71 to 1090 of SEQ ID NO:18.
- the translational region sequence of dgp62 is a sequence capable of expressing all or part of the amino acid sequence of the dgp62 antigen, and may include a start codon and/or a termination codon. 71-1396 sequence.
- the translation region sequence of dgp62 and the fibritin sequence may be linked, for example, the sequence of nucleotide numbers 71 to 1480 in the sequence of SEQ ID NO:19.
- the translation region sequence of Tax is a sequence capable of expressing all or part of the amino acid sequence of the Tax antigen, and may contain a start codon and/or a stop codon. For example, it has four mutations T130A, L131S, L319R and L320S. Examples include those in which the translation region sequence of the mutant Tax antigen having the above four mutations and the sequence encoding the IgE secretory signal peptide for extracellular secretion of the Tax antigen are linked, and the sequence of SEQ ID NO: 20 It is the sequence of base numbers 71-1183 in.
- the 3' untranslated region (3'-UTR) sequence for example, the 3' untranslated region of the human ⁇ -globin gene can be used.
- sequence of the poly A tail (polyA) is, for example, the sequence of base numbers 1142-1241 in the sequence of SEQ ID NO:17.
- the sequences of the cap structure (Cap), 5' untranslated region (5'-UTR), gp46 or Tax translation region, 3' untranslated region (3'-UTR) and poly A tail (polyA) are modified.
- the sequence of the nucleic acid capable of expressing the gp46 antigen may consist of a nucleotide sequence having at least 90%, preferably 95%, more preferably 97% identity with the sequence of SEQ ID NO:17.
- sequence of the nucleic acid capable of expressing the Tax antigen may consist of a nucleotide sequence having at least 90%, preferably 95%, more preferably 97% identity with the sequence of SEQ ID NO:20.
- the length of the poly A tail is not limited, it is, for example, 10 to 250 bases long, preferably 15 to 120 bases long, more preferably 15 to 115 bases long, particularly preferably 20 to 110 bases long.
- the mRNA of the present invention is a sequence comprising a cap structure (Cap), a 5' untranslated region (5'-UTR), a gp46 or Tax translation region and a 3' untranslated region (3'-UTR), and the cap structure (Cap), 5' untranslated region (5'-UTR), a portion consisting of the translation region of gp46 antigen or Tax antigen and 3' untranslated region (3'-UTR) of SEQ ID NO: 17 from 1st to 1141st an mRNA consisting of a nucleotide sequence having at least 90%, preferably 95%, more preferably 97% identity with the sequence, sequence 1 to 1222 of SEQ ID NO: 18, sequence 1 to 1315 of SEQ ID NO: 20 may be
- the nucleic acid encapsulated in the lipid particles may be in any form as long as it is a nucleic acid capable of expressing the HTLV-1 gp46 antigen or Tax antigen.
- single-stranded DNA single-stranded RNA (e.g., mRNA), single-stranded polynucleotide in which DNA and RNA are mixed, double-stranded DNA, double-stranded RNA, DNA-RNA hybrid polynucleotide, DNA and RNA
- double-stranded polynucleotides consisting of two types of polynucleotides in which are mixed, preferably mRNA.
- the nucleotides constituting the nucleic acid to be encapsulated in the lipid particles may be natural or modified nucleotides, but preferably contain at least one modified nucleotide.
- a modified nucleotide may be one in which any portion of the base, sugar, or phosphodiester bond is modified.
- the number of modification sites may be one or two or more.
- Examples of base modifications include cytosine 5-methylation, 5-fluorination, N4-methylation, uracil 5-methylation (thymine), 5-fluorination, adenine N6-methylation, guanine N2 - methylation and the like.
- sugar modifications include 2'-O-methylation of D-ribofuranose.
- a phosphorothioate bond can be mentioned as an example of modification of the phosphodiester bond.
- the modified nucleotide preferably has a modified base portion.
- it may be a pyrimidine nucleotide substituted at position 5, a pseudouridine optionally substituted at position 1, specifically, 5-methylcytidine, Examples include 5-methoxyuridine, 5-methyluridine, pseudouridine, and 1-alkylpseudouridine.
- the 1-alkyl pseudouridine may be 1-(C1-C6 alkyl) pseudouridine, preferably 1-methyl pseudouridine or 1-ethyl pseudouridine.
- More preferred modified nucleotides include 5-methylcytidine, 5-methyluridine, and 1-methylpseudouridine.
- Particularly preferred modified nucleotides include a combination of 5-methylcytidine and 5-methyluridine, or a combination of 5-methylcytidine and 1-methylpseudouridine.
- the nucleic acid capable of expressing the HTLV-1 gp46 antigen or Tax antigen of the present invention can be produced from DNA having a desired base sequence by in vitro transcription reaction.
- Enzymes, buffers, and nucleoside-5'-triphosphate mixtures (adenosine-5'-triphosphate (ATP), guanosine-5'-triphosphate (GTP), cytidine-5'-triphosphate) necessary for in vitro transcription Acid (CTP) and uridine-5'-triphosphate (UTP)) are commercially available (AmpliScribe T7 High Yield Transcription Kit (Epicentre), mMESSAGE m MACHINE T7 Ultra Kit (Life technologies), etc.).
- Cloned DNA such as plasmid DNA or DNA fragments
- plasmid DNA or DNA fragments is used as the DNA used to produce the single-stranded RNA.
- Commercially available plasmid DNAs or DNA fragments may be used, or they can be produced by methods generally known in the art (e.g., Sambrook, J. et al., Molecular Cloning a Laboratory Manual second edition (1989), Rashtchian, A., Current Opinion in Biotechnology, 1995, 6(1), 30-36, Gibson D. G. et al., Science, 2008, 319(5867), 12215-1215 described method, etc.).
- Replacing part or all of unmodified nucleoside-5'-triphosphates with modified nucleoside-5'-triphosphates in an in vitro transcription reaction in order to obtain mRNA with improved stability and/or safety can also replace some or all unmodified nucleotides in mRNA with modified nucleotides (Kormann, M., Nature Biotechnology, 2011, 29, 154-157.).
- a cap structure (Cap0 structure described above) can be introduced at the 5' end of mRNA by a method using a capping enzyme after in vitro transcription reaction. Further, Cap0 can be converted to Cap1 by a method of allowing 2'-O-methyltransferase to act on mRNA having Cap0.
- Commercially available products can be used for the capping enzyme and 2'-O-methyltransferase (eg, Vaccinia Capping System, M2080; mRNA Cap 2'-O-Methyltransferase, M0366, both manufactured by New England Biolab).
- mRNA having a cap structure can be produced according to the protocol attached to the product.
- a cap structure at the 5' end of mRNA can also be introduced by a method other than using an enzyme.
- ARCA or CleanCap registered trademark
- the cap analog structure of ARCA or the Cap1 structure derived from CleanCap can be introduced into mRNA.
- Commercial products can be used for ARCA and CleanCap (ARCA, N-7003; CleanCap Reagent AG, N-7113, both manufactured by TriLink BioTechnologies).
- ARCA and CleanCap ARCA, N-7003; CleanCap Reagent AG, N-7113, both manufactured by TriLink BioTechnologies.
- nucleic acids encapsulated in lipid particles may be purified by methods such as desalting, HPLC (reverse phase, gel filtration, ion exchange, affinity), PAGE, and ultrafiltration.
- a purification process can reduce the production of inflammatory cytokines in an organism to which the nucleic acid is administered by removing impurities.
- the nucleic acid-encapsulating lipid particles of the present invention are produced by a thin film method, a reverse phase evaporation method, an ethanol injection method, an ether injection method, a dehydration-rehydration method, a surfactant dialysis method, a hydration method, a freeze-thaw method, or the like. can do.
- nucleic acid-encapsulating lipid particles can be produced by the method described in International Publication No. 2015/005253.
- the nucleic acid-encapsulating lipid particles of the present invention can also be produced by mixing a nucleic acid solution and a lipid solution in a microchannel. For example, it can be produced using NanoAssemblr (registered trademark) from Precision Nanosystems according to the method described in the attached protocol.
- the particles of the present invention preferably have an average particle size of 30 nm to 300 nm, preferably 30 nm to 200 nm, and more preferably 30 nm to 100 nm.
- the average particle size can be obtained by measuring the volume average particle size based on the principle of the dynamic light scattering method using a device such as Zeta Potential/Particle Sizer NICOMP (registered trademark) 380ZLS (Particle Sizing Systems). can.
- the particles of the present invention can be used to produce compositions for preventing and/or treating diseases caused by HTLV-1 infection.
- Diseases caused by HTLV-1 infection include adult T-cell leukemia (ATL), HTLV-1-associated myelopathy (HAM), HTLV-1-associated uveitis (HU), and the like.
- a lipid particle encapsulating a nucleic acid capable of expressing the gp46 antigen of HTLV-1 and a lipid particle encapsulating a nucleic acid capable of expressing the Tax antigen of HTLV-1 are formulated in the same lipid particle. Although it may be formulated as a separate lipid particle, it is preferably prepared as a separate lipid particle.
- the particles of the present invention can be used to express HTLV-1 gp46 antigen and Tax antigen in vivo or in vitro. That is, lipid particles encapsulating a nucleic acid capable of expressing the HTLV-1 gp46 antigen and lipid particles encapsulating a nucleic acid capable of expressing the HTLV-1 Tax antigen may be administered to a subject. Accordingly, the present invention provides a method of expressing HTLV-1 gp46 and Tax antigens in vitro comprising introducing into a cell a composition containing the above particles. The present invention also provides a method of expressing HTLV-1 gp46 and Tax antigens in vivo comprising administering to a mammal a composition containing the above particles.
- an immune response against HTLV-1 can be induced by expressing the gp46 antigen and Tax antigen of HTLV-1 in vivo.
- HTLV-1 infection can be prevented and/or treated.
- the invention provides a method of inducing an immune response against HTLV-1 comprising administering to a mammal a composition containing the particles described above.
- the present invention also provides a method of preventing and/or treating HTLV-1 infection, comprising administering a composition containing the above particles to a mammal.
- the present invention also includes kits comprising both lipid particles encapsulating nucleic acids capable of expressing the gp46 antigen of HTLV-1 and lipid particles encapsulating nucleic acids capable of expressing the Tax antigen of HTLV-1.
- the particles of the present invention can be used as medicines and as experimental reagents.
- the particles of the present invention are usually added to a carrier such as water, buffer solution, physiological saline, etc., and this formulation (composition) can be introduced into cells (in vitro) or administered to mammals (in vitro). vivo).
- the carrier may be a pharmaceutically acceptable carrier (eg, physiological saline).
- the particles of the present invention can be used in creams and pastes based on fats, fatty oils, lanolin, vaseline, paraffin, wax, resins, plastics, glycols, higher alcohols, glycerin, water, emulsifiers, suspending agents and the like. , ointments, gels, lotions and the like.
- the particles of the present invention can be administered orally, intramuscularly, or intravenously to mammals such as humans, mice, rats, hamsters, guinea pigs, rabbits, pigs, monkeys, cats, dogs, horses, goats, sheep, and cows.
- Parenteral administration can be performed by methods such as administration, rectal administration, transdermal administration, transmucosal administration, subcutaneous administration, and intradermal administration.
- the dosage is about 0.001 to 1 mg, preferably 0.01 to 0.2 mg as the weight of mRNA per adult, once or several times, Intramuscular injection, subcutaneous injection, intradermal injection, drip intravenous injection, or intravenous injection may be used, and the dosage and administration frequency may be appropriately changed depending on the type of disease, symptoms, age, administration method, and the like.
- cells in which the HTLV-1 gp46 antigen and Tax antigen are desired to be expressed e.g., HEK293 cells and their derived cells (HEK293T cells, FreeStyle 293 cells and Expi293 cells), CHO cells, C2C12 mouse myoblasts, immortalized mouse dendritic cells (MutuDC1940)
- HEK293 cells and their derived cells HEK293T cells, FreeStyle 293 cells and Expi293 cells
- CHO cells C2C12 mouse myoblasts
- immortalized mouse dendritic cells e.g., immortalized mouse dendritic cells
- HTLV-1 gp46 antigen and Tax antigen can be detected by detecting HTLV-1 gp46 antigen and Tax antigen protein in a sample by Western blotting, or by detecting peptide fragments specific to HTLV-1 gp46 antigen and Tax antigen. can be analyzed by detecting by mass spectrometry.
- treatment refers to the recovery of clinical symptoms of a patient who has an infectious disease caused by a virus or bacteria, or a disease caused by the infection (e.g., precancerous lesions, cancer, etc.), It means remission, alleviation and/or delay of exacerbation.
- prevention means reducing the incidence of diseases caused by infectious diseases such as viruses or bacteria. Prevention includes reducing the risk of developing diseases, or reducing the severity of those diseases, due to infections such as viruses or bacteria.
- the particles of the present invention are effective in preventing and/or treating the above diseases by inducing a protective immune response.
- the particles of the present invention are expected to be used for HTLV-1 infected persons as preventive and therapeutic agents for diseases caused by HTLV-1.
- Diseases caused by HTLV-1 include adult T-cell leukemia/lymphoma (ATLL), HTLV-1-associated myelopathy (HAM), HTLV-1 uveitis (HU), and the like.
- SU gp46 represents gp46, the surface unit of the envelope protein of HTLV-1.
- gp46-Fib represents a fusion protein between gp46 and the C-terminal region of fibritin.
- dgp62-Fib represents a fusion protein of a protein obtained by deleting the transmembrane region and intracellular region from gp62 and the C-terminal region of fibritin.
- sec Tax mutant represents a fusion protein of a mutated Tax protein and a secretory signal protein.
- Example 1 Preparation of SU gp46 mRNA-001 (1) Preparation of template DNA for in vitro transcription (IVT) of SU gp46 SU gp46 DNA was subjected to PCR to prepare template DNA used for in vitro transcription (IVT). Amplified and purified by A DNA fragment (SEQ ID NO: 1) containing a sequence in which the T7 promoter sequence, the 5′-UTR sequence of human ⁇ -globin, the KOZAK sequence, SU gp46, the 3′-UTR sequence of human ⁇ -globin, and the PolyA sequence were linked in this order was transferred to a plasmid. introduced into 10x Buffer for KOD-Plus-Ver.
- the template DNA (SEQ ID NO: 4) was purified by Wizard SV Gel and PCR Clean-Up System (Promega catalog #A9281).
- RQ1 RNase-Free DNase (8 ⁇ L, Promega catalog # M6101) was mixed and incubated at 37° C. for 15 minutes.
- An 8 M LiCl solution 80 ⁇ L, Sigma-Aldrich catalog # L7026 was mixed and left at ⁇ 30° C. overnight. After centrifugation (4° C., 5200 ⁇ g, 35 minutes), the supernatant was discarded, 70% ethanol was added, and after centrifugation (4° C., 5200 ⁇ g, 10 minutes), the supernatant was discarded and air-dried.
- the resulting residue was dissolved in nuclease-free water (500 ⁇ L) and purified using RNeasy Midi kit (Qiagen catalog # 75144) according to the attached manual.
- the resulting solution 750 ⁇ L
- rApid Alkaline Phosphatase (Roche catalog # 04 898 141 001) buffer (85 ⁇ L)
- enzyme 32 ⁇ L
- the resulting solution was purified using the RNeasy Midi kit (Qiagen catalog #75144) according to the attached manual to obtain the target mRNA.
- the same experimental procedure was performed twice in total, and the obtained mRNA solutions were combined to obtain the target mRNA.
- the resulting mRNA has the sequence of SEQ ID NO:17.
- Example 2 Preparation of gp46-Fib mRNA-002 (1) Preparation of template DNA for in vitro transcription (IVT) of gp46-Fib DNA was purified after amplification by PCR. A DNA fragment (SEQ ID NO: 5) containing a sequence in which the T7 promoter sequence, the 5′-UTR sequence of human ⁇ -globin, the KOZAK sequence, gp46-Fib, the 3′-UTR sequence of human ⁇ -globin, and the PolyA sequence were linked in this order. introduced into a plasmid. 10 ⁇ Buffer for KOD-Plus-Ver. 2 (80 ⁇ L, Toyobo Co., Ltd.
- the template DNA (SEQ ID NO: 6) was purified by Wizard SV Gel and PCR Clean-Up System (Promega catalog #A9281).
- RQ1 RNase-Free DNase (8 ⁇ L, Promega catalog # M6101) was mixed and incubated at 37° C. for 15 minutes.
- An 8 M LiCl solution 80 ⁇ L, Sigma-Aldrich catalog # L7026 was mixed and left at ⁇ 30° C. overnight. After centrifugation (4° C., 5200 ⁇ g, 35 minutes), the supernatant was discarded, 70% ethanol was added, and after centrifugation (4° C., 5200 ⁇ g, 10 minutes), the supernatant was discarded and air-dried.
- the resulting residue was dissolved in nuclease-free water (500 ⁇ L) and purified using RNeasy Midi kit (Qiagen catalog # 75144) according to the attached manual.
- the resulting solution 750 ⁇ L
- rApid Alkaline Phosphatase (Roche catalog # 04 898 141 001) buffer (85 ⁇ L)
- enzyme 32 ⁇ L
- the resulting solution was purified using the RNeasy Midi kit (Qiagen catalog #75144) according to the attached manual to obtain the target mRNA.
- the same experimental procedure was performed twice in total, and the obtained mRNA solutions were combined to obtain the target mRNA.
- the resulting mRNA has the sequence of SEQ ID NO:18.
- Example 3 Preparation of dgp62-Fib mRNA-003 (1) Preparation of template DNA for in vitro transcription (IVT) of dgp62-Fib DNA was purified after amplification by PCR. A DNA fragment (SEQ ID NO: 7) containing a sequence in which the T7 promoter sequence, the 5′-UTR sequence of human ⁇ -globin, the KOZAK sequence, the dgp62-Fib, the 3′-UTR sequence of human ⁇ -globin, and the PolyA sequence are linked in this order. introduced into a plasmid. 10x Buffer for KOD-Plus-Ver. 2 (80 ⁇ L, Toyobo Co., Ltd.
- the template DNA (SEQ ID NO: 8) was purified by Wizard SV Gel and PCR Clean-Up System (Promega catalog #A9281).
- RQ1 RNase-Free DNase (8 ⁇ L, Promega catalog # M6101) was mixed and incubated at 37° C. for 15 minutes.
- An 8 M LiCl solution 80 ⁇ L, Sigma-Aldrich catalog # L7026 was mixed and left at ⁇ 30° C. overnight. After centrifugation (4° C., 5200 ⁇ g, 35 minutes), the supernatant was discarded, 70% ethanol was added, and after centrifugation (4° C., 5200 ⁇ g, 10 minutes), the supernatant was discarded and air-dried.
- the resulting residue was dissolved in nuclease-free water (500 ⁇ L) and purified using RNeasy Midi kit (Qiagen catalog # 75144) according to the attached manual.
- the resulting solution 750 ⁇ L
- rApid Alkaline Phosphatase (Roche catalog # 04 898 141 001) buffer (85 ⁇ L)
- enzyme 32 ⁇ L
- the resulting solution was purified using the RNeasy Midi kit (Qiagen catalog #75144) according to the attached manual to obtain the target mRNA.
- the same experimental procedure was performed twice in total, and the obtained mRNA solutions were combined to obtain the target mRNA.
- the resulting mRNA has the sequence of SEQ ID NO:19.
- the template DNA (SEQ ID NO: 10) was purified by Wizard SV Gel and PCR Clean-Up System (Promega catalog #A9281).
- RQ1 RNase-Free DNase (8 ⁇ L, Promega catalog # M6101) was mixed and incubated at 37° C. for 15 minutes.
- An 8 M LiCl solution 80 ⁇ L, Sigma-Aldrich catalog # L7026 was mixed and left at ⁇ 30° C. overnight. After centrifugation (4° C., 5200 ⁇ g, 35 minutes), the supernatant was discarded, 70% ethanol was added, and after centrifugation (4° C., 5200 ⁇ g, 10 minutes), the supernatant was discarded and air-dried.
- the resulting residue was dissolved in nuclease-free water (500 ⁇ L) and purified using RNeasy Midi kit (Qiagen catalog # 75144) according to the attached manual.
- the resulting solution 750 ⁇ L
- rApid Alkaline Phosphatase (Roche catalog # 04 898 141 001) buffer (85 ⁇ L)
- enzyme 32 ⁇ L
- the resulting solution was purified using the RNeasy Midi kit (Qiagen catalog #75144) according to the attached manual to obtain the target mRNA.
- the same experimental procedure was performed twice in total, and the obtained mRNA solutions were combined to obtain the target mRNA.
- the resulting mRNA has the sequence of SEQ ID NO:20.
- Example 5 Preparation of SU gp46 mRNA-005 (1) Preparation of template DNA for in vitro transcription (IVT) of SU gp46 It was carried out in the same manner as in Example 1-(1).
- RQ1 RNase-Free DNase (30 ⁇ L, Promega catalog # M6101) was mixed and incubated at 37° C. for 15 minutes.
- An 8 M LiCl solution (1500 ⁇ L, Sigma-Aldrich catalog # L7026) was mixed and left at -20° C. overnight. After centrifugation (4° C., 5250 ⁇ g, 30 minutes), the supernatant was discarded, 70% ethanol was added, and after centrifugation (4° C., 5250 ⁇ g, 10 minutes), the supernatant was discarded and air-dried. The resulting residue was dissolved in nuclease-free water and purified using RNeasy Maxi kit (Qiagen catalog #75162) according to the attached manual.
- the obtained eluate (12 mL, 12.0 mg in terms of UV), Nuclease-free water (120 ⁇ L), rApid Alkaline Phosphatase (Roche catalog # 04 898 141 001) buffer (1400 ⁇ L) and enzyme (480 ⁇ L) were mixed. , and incubated at 37° C. for 30 minutes. After incubation at 75°C for 2 minutes, 8M LiCl solution (7000 ⁇ L, Sigma-Aldrich catalog # L7026) was mixed and allowed to stand overnight at -20°C.
- the resulting mRNA was subjected to reverse phase chromatography (Column: PLRP-S, 4000 ⁇ , 10 ⁇ m, 10 x 200 mm (Agilent), Buffer A: 5% acetonitrile, 400 mM triethylamine acetate (pH 7.0), Buffer B: 25% acetonitrile, 400 mM acetic acid Triethylamine (pH 7.0), Gradient B%: 27.5% to 35% (20 min), Flow rate: 5 mL/min, Temperature: 80° C.). The desired fraction was collected and desalted (3.4 mg in terms of UV) by ultrafiltration (Amicon Ultra-15 (MWCO: 30 kDa)).
- the obtained mRNA has the sequence of SEQ ID NO: 17. It was analyzed with the LabChip GX Touch Standard RNA Reagent Kit (PerkinElmer catalog #CLS960010) and confirmed to be of the desired length.
- Example 6 Preparation of sec Tax mutant mRNA-006 (1) Preparation of template DNA for in vitro transcription (IVT) of sec Tax mutant It was carried out in the same manner as in Example 4-(1).
- RQ1 RNase-Free DNase (30 ⁇ L, Promega catalog # M6101) was mixed and incubated at 37° C. for 15 minutes.
- An 8 M LiCl solution (1500 ⁇ L, Sigma-Aldrich catalog # L7026) was mixed and left at -20° C. overnight. After centrifugation (4° C., 5250 ⁇ g, 30 minutes), the supernatant was discarded, 70% ethanol was added, and after centrifugation (4° C., 5250 ⁇ g, 10 minutes), the supernatant was discarded and air-dried. The resulting residue was dissolved in nuclease-free water and purified using RNeasy Maxi kit (Qiagen catalog #75162) according to the attached manual.
- the obtained eluate (12 mL, 12.6 mg in terms of UV), Nuclease-free water (100 ⁇ L), rApid Alkaline Phosphatase (Roche catalog # 04 898 141 001) buffer (1400 ⁇ L) and enzyme (500 ⁇ L) were mixed. , and incubated at 37° C. for 30 minutes. After incubation at 75°C for 2 minutes, 8M LiCl solution (7000 ⁇ L, Sigma-Aldrich catalog # L7026) was mixed and allowed to stand overnight at -20°C.
- the resulting mRNA was subjected to reverse phase chromatography (Column: PLRP-S, 4000 ⁇ , 10 ⁇ m, 10 x 200 mm (Agilent), Buffer A: 5% acetonitrile, 400 mM triethylamine acetate (pH 7.0), Buffer B: 25% acetonitrile, 400 mM acetic acid Triethylamine (pH 7.0), Gradient B%: 27.5% to 35% (20 min), Flow rate: 5 mL/min, Temperature: 80° C.). The desired fraction was collected and desalted (3.7 mg in terms of UV) by ultrafiltration (Amicon Ultra-15 (MWCO: 30 kDa)).
- the obtained mRNA has the sequence of SEQ ID NO:20. It was analyzed with the LabChip GX Touch Standard RNA Reagent Kit (PerkinElmer catalog #CLS960010) and confirmed to be of the desired length.
- Example 7 Preparation of gp46-Fib mRNA-007 (1) Preparation of template DNA for in vitro transcription (IVT) of gp46-Fib It was carried out in the same manner as in Example 2-(1).
- RQ1 RNase-Free DNase 25 ⁇ L, Promega catalog # M6101
- An 8 M LiCl solution 500 ⁇ L, Sigma-Aldrich catalog # L7026
- the resulting residue was dissolved in nuclease-free water and purified using RNeasy Maxi kit (Qiagen catalog #75162) according to the attached manual.
- the obtained mRNA has the sequence of SEQ ID NO: 18. It was analyzed with the LabChip GX Touch Standard RNA Reagent Kit (PerkinElmer catalog #CLS960010) and confirmed to be of the desired length.
- Example 8 Preparation of sec Tax mutant mRNA-008 (1) Preparation of template DNA for in vitro transcription (IVT) of sec Tax mutant It was carried out in the same manner as in Example 4-(1).
- RQ1 RNase-Free DNase 25 ⁇ L, Promega catalog # M6101
- An 8 M LiCl solution 500 ⁇ L, Sigma-Aldrich catalog # L7026
- the resulting residue was dissolved in nuclease-free water and purified using RNeasy Maxi kit (Qiagen catalog #75162) according to the attached manual.
- the obtained eluate (3 mL, 3.5 mg in terms of UV), Nuclease-free water (359 ⁇ L), rApid Alkaline Phosphatase (Roche catalog # 04 898 141 001) buffer (450 ⁇ L) and enzyme (691 ⁇ L) were mixed. , and incubated at 37° C. for 30 minutes. After incubating at 75° C. for 2 minutes, purification was performed using RNeasy Maxi kit according to the attached manual to obtain target mRNA (4 mL, 2.8 mg in terms of UV).
- the obtained mRNA has the sequence of SEQ ID NO:20. It was analyzed with the LabChip GX Touch Standard RNA Reagent Kit (PerkinElmer catalog #CLS960010) and confirmed to be of the desired length.
- the mRNA obtained in Examples 1 to 8 was diluted with a citrate buffer (20 mM Citrate Buffer, pH 4.0).
- the above lipid solution and mRNA solution were mixed in a microchannel using a NanoAssembler BenchTop (Precision Nanosystems Inc.) so that the total lipid weight ratio to mRNA was the value shown in Table 1 and the volume ratio was 1:3. to obtain a coarse dispersion of nucleic acid-lipid particles. Ethanol is removed by dialysis (Float-A-Lyzer G2, MWCO: 1,000 kD, Spectra/Por) for 12-18 hours against a dispersion of nucleic acid lipid particles with about 25-50 times the amount of buffer solution, A dispersion of purified mRNA-encapsulating nucleic acid-lipid particles was obtained.
- LP1 was synthesized according to the method described in Example 23 of WO2015/005253, and LP2 was synthesized according to the method described in Example 28 of WO2015/005253.
- the amount of mRNA in the nucleic acid-lipid particle dispersion was measured by one of the following methods.
- the nucleic acid lipid particle dispersion was diluted with 1.0% Triton X-100 and measured by reversed-phase chromatography (System: Agilent 1260 series, Column: Bioshell A400 Protein C4 (10 cm x 4.6 mm, 3.4 ⁇ m ) (SUPELCO), Buffer A: 0.1 M triethylamine acetate (pH 7.0), Buffer B: acetonitrile, (B%): 5-50% (0-15 min), Flow Rate: 1 mL / min, Temperature: 70 ° C. , Detection: 260 nm).
- the nucleic acid-lipid particle dispersion was diluted and dissolved in 90% methanol, and the amount of mRNA in the nucleic acid-lipid particles was measured with an ultraviolet-visible spectrophotometer (PerkinElmer, LAMBDA (trademark) 465).
- the mRNA concentration was calculated by the following formula. ⁇ [absorbance at 260 nm]-[absorbance at 350 nm] ⁇ x 40 x dilution factor ( ⁇ g/mL)
- the amount of each lipid in the dispersion of nucleic acid lipid particles was measured by reversed-phase chromatography (System: DIONEX UltiMate 3000, Column: XSelect CSH C18 (130 ⁇ , 3.5 ⁇ m, 3.0 mm ⁇ 150 mm,) (Waters catalog # 186005263), Buffer A: 0.2% formic acid, Buffer B: 0.2% formic acid, methanol, (B%): 75-100% (0-6min), 100% (6-15min), Flow Rate: 0 .45 mL/min, Temperature: 50°C, Detection: Corona CAD (Charged Aerosol Detector)).
- the ratio of total lipid amount to mRNA was calculated by the following formula. [Total lipid concentration]/[mRNA concentration] (wt/wt)
- Table 2 shows the results of the characteristic evaluation.
- HIV-1 LTR and HTLV-1 LTR Reporter Assay 350 ng of plasmid expressing Tax wild-type, Tax mutant or secretory Tax mutant, 100 ng of HIV-1 LTR reporter plasmid or HTLV-1 LTR reporter plasmid, In addition, 50 ng of pRG-RK plasmid (Promega) for transfection efficiency correction and a total of 500 ng of the plasmid were transfected into HEK293T cells using TransIT-LT1 gene introduction reagent (Takara).
- Example 2 Administration of Example 12 to C3H Mice C3H/HeJJcl mice were obtained from CLEA Japan and conditioned. At 2-week intervals, Example 12 was administered at 5 ⁇ g mRNA/20 ⁇ L/mouse into the cleansed triceps surae muscles of anesthetized mice. The first dose was administered to the right leg and the second dose to the left leg. Buffer was used for adjusting the concentration of lipid particles and for the negative control group.
- the supernatant was discarded, and red blood cells were lysed using DB Pharm Lyse Lysing buffer (BECTON DICKINSON). After centrifugation, the cell suspension resuspended in RPMI 1640 was passed through mini Cell Strainers (Hitec Co., Ltd., Cat. HT-AMS-14002). After centrifugation, the supernatant was discarded, the cells were resuspended, and the cell concentration was determined.
- DB Pharm Lyse Lysing buffer BECTON DICKINSON
- cell culture medium RPMI 1640 with 10% Fetal Bovine Serum (inactivated and filtered, HyClone), 1% Penicillin-Streptomycin Mixed Solution (nacalai tesque), 1% Sodium Pyruvate (gibco ), 1% MEM Non-Essential Amino Acids (gibco), 1% HEPES Buffer Solution (gibco), 1% StemSure Monothioglycerol Solution (FUJIFILM) was added) to adjust the cell concentration. Centrifugation was performed at 1500 RPM for 5 minutes at 4°C.
- Tax-specific CTL induction level 3 x 10 6 prepared mouse spleen cells were centrifuged and the supernatant was discarded. The process of resuspending the cells with 1X Dulbecco's Phosphate Buffered Saline (gibco), centrifuging and discarding the supernatant was repeated twice. After that, TruStain FcX Antibody (BioLegend) diluted 20-fold with 1X PBS was added to the cells and allowed to stand at room temperature for 5 minutes. 5 ⁇ L of H-2D K HTLV-1 Tax38-46 Tetramer-ARLHTHALL-PE (MBL) was added to each sample and incubated at 37° C., 5% CO 2 for 15 minutes.
- MBL H-2D K HTLV-1 Tax38-46 Tetramer-ARLHTHALL-PE
- APC/FireTM 750 anti-mouse CD3 Antibody (BioLegend) and Anti-CD8 (Mouse) mAb-FITC (MBL) adjusted to a final concentration of 100-fold dilution were added to the sample. , and allowed to stand in the dark for 30 minutes. The supernatant was discarded by centrifugation and the cells were washed twice with 1X PBS. Cells were finally resuspended in 400 ⁇ L PBS and labeled cells were detected by FACSVerse (BD) and analyzed by FlowJo (confirmation). Centrifugation was performed at 1500 RPM for 5 minutes at 4°C.
- Anti-Tax Antibody Titer in Mouse Blood Tax (MYBiosource) recombinant protein was added to a 96-well flat-bottom plate and allowed to stand overnight at 4° C. in order to use it as a solid-phase antigen.
- a standard curve dilution series was prepared by 7 steps of 3-fold dilution of Mouse IgG (SouthernBiotech) from the highest concentration of 0.25 ⁇ g/mL. Each well was washed, a blocking solution was added, and the wells were allowed to stand at room temperature for 1 hour. Serum samples were prepared in 7 steps from 100-fold dilution of the highest concentration to 4-fold dilution using blocking solution.
- the blocked plate was washed and the diluted sample was added to the plate and allowed to stand at room temperature for 1 hour.
- a detection antibody Goat Anti-Mouse IgG, Human ads-HRP (SouthernBiotech) was diluted 3000-fold in blocking solution and added to the washed wells. After 1 hour, the plate was washed, TMB Microwell Peroxidase Substrate System (seracare) was added, allowed to stand for 2 to 3 minutes, and the reaction was stopped using TMB Stop Solution (KPL, Cat.51500-0021).
- the corrected absorbance obtained by subtracting the absorbance at 540 nm from the absorbance at 450 nm was used for analysis, and the anti-gp46 antibody titer and the anti-Tax antibody titer were calculated.
- the blocking solution was 1X Dulbecco's Phosphate Buffered Saline (gibco) containing 1% Bovine Serum Albumin (Sigma) and 0.05% Tween (BIO-RAD), and 0.05% Tween was added for washing.
- 1X Dulbecco's Phosphate Buffered Saline ((10X) gibco) was performed in triplicate.
- Example 13 and 14 were administered to the upper arm of monkeys once/two weeks, a total of 4 times. The first dose was administered to the right upper arm, followed by alternate administration to the left and right. For the dose of lipid particles, 25 ⁇ g mRNA of each of Example 13 and Example 14 were mixed in equal amounts, and 50 ⁇ g mRNA/200 ⁇ L/body was administered per administration.
- a monkey IgG concentration standard curve dilution series was prepared by diluting a monkey IgG solution (manufacturer) with a blocking solution from the highest concentration of 0.25 ⁇ g/mL in 8 steps by 3-fold dilution. A sample dilution solution and a standard curve dilution solution were added, and the plate was washed with a plate washer after standing at room temperature for 1 hour.
- an HRP-labeled anti-monkey IgG antibody (Sigma-Aldrich) was diluted 4000-fold with a blocking solution, added to the plate, and allowed to stand at room temperature for 1 hour.
- TMB Microwell Peroxidase Substrate System (SERACARE Life Sciences) was added and allowed to stand for 10 minutes.
- TMB Stop Solution (SERACARE Life Sciences) was used as a reaction stop solution.
- Absorbance at a wavelength of 450 nm (reference wavelength of 540 nm) was measured using a plate reader, and the corrected absorbance (Delta) obtained by subtracting the absorbance measured at 540 nm from the absorbance measured at 450 nm was used for analysis.
- a standard curve was created from the monkey IgG concentration and Delta of the standard curve using Nonlinear Regression: 4 Parameter.
- the anti-gp46 and Tax antibody concentrations of the sample were calculated from the calibration curve, the dilution ratio of the measurement sample, and Delta.
- PBMCs isolated from monkey peripheral blood using Ficoll were added to RPMI Complete medium (10% FBS [Sigma-Aldrich], 1% PS [Penicilin-Streptomycin Mixed Solution, Nacalai Tesque], 1 mM Sodium Pyruvate [Thermo Fisher Scientific], 10 mM HEPES [Thermo Fisher Scientific], 1 x StemSure [Fujifilm Wako Pure Chemical], 1 x MEM Non-Essential Amino Acids Solution [Thyscient] The cells were adjusted to 10 6 cells/mL and seeded on an IFN- ⁇ ELISpot plate (MABTech) at 100 ⁇ L/well.
- MABTech IFN- ⁇ ELISpot plate
- Tax epitope peptide pool prepared to a final concentration of 0.1% (v/v) in RPMI Complete medium or gp46 recombinant protein (RayBiotech) prepared to 1 ⁇ g/mL was added at 100 ⁇ L/well, Cultured for 48 hours under conditions of 37° C. and 5% CO 2 .
- Antigen-specific IFN- ⁇ producing cells were detected using the Monkey IFN- ⁇ ELISpot PLUS kit (HRP) (MABTech). The number of antigen-specific IFN- ⁇ -producing cells was measured using an ELISPOT analyzer (CTL).
- mice blood gp46-specific total IgG antibody titer A gp46 (Ray Biotech Inc.) recombinant protein was added to a 96-well flat-bottom plate and allowed to stand overnight at 4°C to use as a solid-phase antigen.
- a standard curve dilution series was prepared by 7 steps of 3-fold dilution of Mouse IgG (SouthernBiotech) from the highest concentration of 0.25 ⁇ g/mL. Each well was washed, a blocking solution was added, and the wells were allowed to stand at room temperature for 1 hour. Serum samples were prepared in 7 steps from 100-fold dilution of the highest concentration to 4-fold dilution using blocking solution.
- the blocked plate was washed, and the diluted sample was added to the plate and allowed to stand at room temperature for 1 hour.
- a detection antibody Goat Anti-Mouse IgG, Human ads-HRP (SouthernBiotech) was diluted 3000-fold in blocking solution and added to the washed wells. After 1 hour, the plate was washed, TMB Microwell Peroxidase Substrate System (seracare) was added, allowed to stand for 2 to 3 minutes, and the reaction was stopped using TMB Stop Solution (KPL, Cat.51500-0021).
- the corrected absorbance obtained by subtracting the absorbance at 540 nm from the absorbance at 450 nm was used for analysis to calculate the anti-gp46 antibody titer and the anti-Tax antibody titer.
- the blocking solution was 1X Dulbecco's Phosphate Buffered Saline (gibco) containing 1% Bovine Serum Albumin (Sigma) and 0.05% Tween (BIO-RAD), and 0.05% Tween was added for washing.
- IX Dulbecco's Phosphate Buffered Saline ((10X) gibco) was performed in triplicate.
- mice 10 6 /well of prepared mouse spleen cells were seeded in 96-well U-bottom plates (FALCON), gp46 and Tax adjusted to a final concentration of 10 ⁇ g/mL Stimulation was with pooled peptide (Eurofins) at 37° C., 5% CO 2 . After 24 hours, the culture supernatant was collected, and IFN- ⁇ (R&D Systems) and IL-2 (R&D Systems) production was measured according to the protocol of the kit.
- FALCON pooled peptide
- Example 12 CTL Induction Level and Blood Anti-Tax Antibody Titer by Example 12
- the CTL induction level in C3H mice administered with Example 12 was evaluated (FIG. 2).
- Example 12 induced Tax-specific CTL and a blood anti-Tax antibody response.
- a DNA fragment containing a sequence in which the T7 promoter sequence, the 5′-UTR sequence of human ⁇ -globin, the KOZAK sequence, the translation region of gp46-Fib, the 3′-UTR sequence of human ⁇ -globin and the polyA sequence are linked in order were introduced (Examples 25 to 29 were carried out using the plasmids into which the DNA fragments of SEQ ID NOS: 21 to 25 were introduced, respectively).
- RQ1 RNase-Free DNase (7.5 ⁇ L, Promega catalog # M6101) was mixed and incubated at 37° C. for 30 minutes. 10 M ammonium acetate solution (100 ⁇ L,) was mixed and allowed to stand at ⁇ 20° C. for 2 hours. After centrifugation (4° C., 15000 ⁇ g, 30 minutes), the supernatant was discarded, 70% ethanol was added, and after centrifugation (4° C., 15000 ⁇ g, 10 minutes), the supernatant was discarded and air-dried. The resulting residue was dissolved in nuclease-free water and purified with NucleoSpin (Macherey-Nagel catalog # 740948.50) to obtain the desired mRNA.
- the resulting mRNA has the sequences of SEQ ID NOs: 31-35, has a cap1 structure at the 5' end, and has cytidine and uridine substituted with 5-methylcytidine and 5-methyluridine, respectively. It was analyzed with the LabChip GX Touch Standard RNA Reagent Kit (PerkinElmer catalog #CLS960010) and confirmed to be of the desired length.
- Example 30 to 34 Preparation of mRNA-encapsulating nucleic acid-lipid particles obtained in Examples 25-29 (1) Preparation of mRNA-encapsulating nucleic acid-lipid particles Example 25 instead of the mRNA described in Examples 1-8 Nucleic acid-lipid particles shown in Table 3 were prepared in the same manner as in Examples 9 to 24 using the mRNAs obtained in 1 to 29, respectively.
- gp46 Protein Expression Analysis Examples 30-34 were added to CHO-S cells (Thermo Fisher Scientific) such that the mRNA concentration in the medium was 3 ⁇ g/mL. As a negative control, the same amount of buffer as that of the particles of Examples 35-39 was added. The culture supernatant was collected 3 days after the addition. The gp46 protein in the culture supernatant was obtained by immobilizing the culture supernatant diluted 10-fold with D-PBS on a 96 half well plate and performing an Enzyme-Linked Immunosorbent Assay (ELISA) using the serum of mice administered with Example 10. ) detected by the method.
- ELISA Enzyme-Linked Immunosorbent Assay
- the present invention can be used for prevention and/or treatment of HTLV-1 infection.
- SEQ ID NO: 1 nucleotide sequence of template plasmid DNA for SU gp46 IVT
- SEQ ID NO: 2 nucleotide sequence of sense primer
- SEQ ID NO: 3 nucleotide sequence of antisense primer
- SEQ ID NO: 4 template for in vitro transcription (IVT) of SU gp46
- Nucleotide sequence of DNA SEQ ID NO: 5: nucleotide sequence of template plasmid DNA for HTLV-I gp46-Fib IVT
- SEQ ID NO: 6 nucleotide sequence of template DNA for in vitro transcription (IVT) of gp46-Fib
- SEQ ID NO: 7 HTLV- Nucleotide sequence of template plasmid DNA for I dgp62-Fib IVT
- SEQ ID NO: 8 Nucleotide sequence of template DNA for in vitro transcription (IVT) of dgp62-Fib
- SEQ ID NO: 9 Template plasmid DNA
Abstract
Description
(1)ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原を発現させることができる核酸を封入した脂質粒子であって、脂質が一般式(Ia)で表されるカチオン性脂質、又はその薬学的に許容される塩を含む前記粒子。
R1及びR2は、独立して、C1-C3アルキル基を示し;
L1は、C2-C4アルカノイルオキシ基を1若しくは複数個有していてもよいC17-C19アルケニル基を示し;
L2は、C2-C4アルカノイルオキシ基を1若しくは複数個有していてもよいC10-C19アルキル基、又はC2-C4アルカノイルオキシ基を1若しくは複数個有していてもよいC10-C19アルケニル基を示し;
pは、3、又は4である。
(2)一般式(Ia)中のR1及びR2が、共にメチル基である、(1)に記載の粒子。
(3)一般式(Ia)中のpが、3である(1)又は(2)に記載の粒子。
(4)一般式(Ia)中のL1が、アセトキシ基を1若しくは複数個有していてもよいC17-C19アルケニル基である、(1)~(3)のいずれかに記載の粒子。
(5)一般式(Ia)中のL2が、アセトキシ基を1若しくは複数個有していてもよいC10-C12アルキル基、又はアセトキシ基を1若しくは複数個有していてもよいC10-C19アルケニル基である、(1)~(4)のいずれかに記載の粒子。
(6)一般式(Ia)中のL2が、アセトキシ基を1若しくは複数個有していてもよいC10-C12アルキル基、又はアセトキシ基を1若しくは複数個有していてもよいC17-C19アルケニル基である、(1)~(4)のいずれかに記載の粒子。
(7)一般式(Ia)中のL1が、(R)-11-アセチルオキシ-cis-8-ヘプタデセニル基、cis-8-ヘプタデセニル基、又は(8Z,11Z)-ヘプタデカジエニル基である(1)~(6)のいずれかに記載の粒子。
(8)一般式(Ia)中のL2が、デシル基、cis-7-デセニル基、ドデシル基、又は(R)-11-アセチルオキシ-cis-8-ヘプタデセニル基である、(1)~(7)のいずれかに記載の粒子。
(9)カチオン性脂質が下記の構造式:
(10)カチオン性脂質が下記の構造式:
(11)カチオン性脂質が下記の構造式:
(12)脂質が、さらに、両親媒性脂質、ステロール類及びPEG脂質を含む(9)又は(10)に記載の粒子。
(13)脂質が、さらに、両親媒性脂質、ステロール類及びPEG脂質を含む(11)に記載の粒子。
(14)両親媒性脂質が、ジステアロイルホスファチジルコリン、ジオレオイルホスファチジルコリン及びジオレオイルホスファチジルエタノールアミンからなる群より選択される少なくとも1つである(12)に記載の粒子。
(15)両親媒性脂質が、ジステアロイルホスファチジルコリン、ジオレオイルホスファチジルコリン及びジオレオイルホスファチジルエタノールアミンからなる群より選択される少なくとも1つである(13)に記載の粒子。
(16)ステロール類がコレステロールである(12)又は(14)に記載の粒子。
(17)ステロール類がコレステロールである(13)又は(15)に記載の粒子。
(18)PEG脂質が、1,2-ジミリストイル-sn-グリセロール メトキシポリエチレン グリコール及び/又はN-[メトキシ ポリ(エチレングリコール)2000]カルバモイル]-1,2-ジミリスチルオキシプロピル-3-アミンである(12)、(14)、(16)のいずれかに記載の粒子。
(19)PEG脂質が、1,2-ジミリストイル-sn-グリセロール メトキシポリエチレン グリコール及び/又はN-[メトキシ ポリ(エチレングリコール)2000]カルバモイル]-1,2-ジミリスチルオキシプロピル-3-アミンである(13)、(15)、(17)のいずれかに記載の粒子。
(20)両親媒性脂質、ステロール類、カチオン性脂質、及びPEG脂質の脂質組成が、モル量にて、両親媒性脂質が5~25%、ステロール類が10~55%、カチオン性脂質が40~65%、PEG脂質が1~5%である(12)~(19)のいずれかに記載の粒子。
(21)両親媒性脂質が10~25%である(20)に記載の粒子。
(22)両親媒性脂質、ステロール類、カチオン性脂質、及びPEG脂質の脂質組成が、モル量にて、両親媒性脂質が5~15%、ステロール類が35~50%、カチオン性脂質が40~55%、PEG脂質が1~3%である(12)、(14)、(16)、(18)のいずれかに記載の粒子。
(23)両親媒性脂質が10~15%、ステロール類が35~45%、カチオン性脂質が40~50%、PEG脂質が1~2.5%である(22)に記載の粒子。
(24)PEG脂質が1~2%である(23)に記載の粒子。
(25)両親媒性脂質、ステロール類、カチオン性脂質、及びPEG脂質の脂質組成が、モル量にて、両親媒性脂質が10~25%、ステロール類が10~50%、カチオン性脂質が40~65%、PEG脂質が1~3%である(13)、(15)、(17)、(19)のいずれかに記載の粒子。
(26)ステロール類が10~45%、カチオン性脂質が42.5~65%、PEG脂質が1~2.5%である(25)に記載の粒子。
(27)PEG脂質が1~2%である(26)に記載の粒子。
(28)核酸重量に対する総脂質重量の比率が15~30である(20)~(27)のいずれかに記載の粒子。
(29)核酸重量に対する総脂質重量の比率が15~25である(28)に記載の粒子。
(30)核酸重量に対する総脂質重量の比率が17.5~22.5である(29)に記載の粒子。
(32)オリゴマー化ドメインがフィブリチンである(31)に記載の粒子。
(33)ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原が配列番号14のアミノ酸配列と少なくとも95%の同一性を有するアミノ酸配列からなる(31)又は(32)に記載の粒子。
(34)ヒトT細胞白血病ウイルス1型(HTLV-1)のTax抗原が、配列番号11のアミノ酸配列に対して、T130A、L131S、L319R及びL320Sからなる群から選択される変異の少なくとも1つを有し、該変異アミノ酸以外のアミノ酸配列を比較した場合、配列番号11のアミノ酸配列と少なくとも95%の同一性を有するアミノ酸配列からなる(1)~(33)のいずれかに記載の粒子。
(35)ヒトT細胞白血病ウイルス1型(HTLV-1)のTax抗原が、配列番号11のアミノ酸配列に対して、T130A、L131S、L319R及びL320Sの変異を有し、該変異アミノ酸以外のアミノ酸配列を比較した場合、配列番号11のアミノ酸配列と少なくとも95%の同一性を有するアミノ酸配列からなる(34)に記載の粒子。
(36)ヒトT細胞白血病ウイルス1型(HTLV-1)のTax抗原が、シグナルペプチドとの融合タンパク質である(1)~(35)のいずれかに記載の粒子。
(37)シグナルペプチドが配列番号13のアミノ酸配列の1番目~18番目のアミノ酸配列からなるペプチドである(36)に記載の粒子。
(38)ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原を発現させることができる核酸が、キャップ構造(Cap)、5’非翻訳領域(5’-UTR)gp46抗原又はTax抗原の翻訳領域、3’非翻訳領域(3’-UTR)及びポリA尾部(polyA)を含むmRNAである(31)~(37)のいずれかに記載の粒子。
(39)ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原を発現させることができる核酸の配列が、配列番号17又は18の配列と少なくとも90%の同一性を有するヌクレオチド配列からなる(38)に記載の粒子。
(40)ヒトT細胞白血病ウイルス1型(HTLV-1)のTax抗原を発現させることができる核酸の配列が、配列番号20の配列と少なくとも90%の同一性を有するヌクレオチド配列からなる(38)に記載の粒子。
(42)修飾ヌクレオチドが、5位が置換したピリミジンヌクレオチド及び/又は1位が置換していてもよいシュードウリジンの少なくとも1個を含む(41)に記載の粒子。
(43)修飾ヌクレオチドが、5-メチルシチジン、5-メトキシウリジン、5-メチルウリジン、シュードウリジン、及び1-アルキルシュードウリジンからなる群から選ばれる少なくとも1個を含む(41)に記載の粒子。
(44)修飾ヌクレオチドが、5-メチルシチジン、5-メチルウリジン、及び1-メチルシュードウリジンからなる群から選ばれる少なくとも1個を含む(41)に記載の粒子。
(45)平均粒子径が30~300nmである(1)~(44)のいずれかに記載の粒子。
(47)(1)~(45)のいずれかに記載の粒子を含有する、組成物。
(48)ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原をin vivo又はin vitroで発現させるための(47)に記載の組成物。
(49)医薬として用いられる(47)又は(48)に記載の組成物。
(50)ヒトT細胞白血病ウイルス1型(HTLV-1)に対する免疫反応を誘導するための(49)に記載の組成物。
(51)ヒトT細胞白血病ウイルス1型(HTLV-1)感染を予防及び/又は治療するための(49)又は(50)に記載の組成物。
(52)HTLV-1感染者に対して、成人T細胞白血病・リンパ腫(ATLL)、HTLV-1関連脊髄症(HAM)及びHTLV-1ぶどう膜炎(HU)からなる群から選択されるHTLV-1に起因する疾患の発症の予防及び/又は治療するための(49)又は(50)の組成物。
(53)(47)~(50)のいずれかに記載の組成物を細胞に導入することを含む、ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原をin vitroで発現させる方法。
(54)(47)~(51)のいずれかに記載の組成物を哺乳動物に投与することを含む、ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原をin vivoで発現させる方法。
(55)(49)又は(50)に記載の組成物を哺乳動物に投与することを含む、ヒトT細胞白血病ウイルス1型(HTLV-1)に対する免疫反応を誘導する方法。
(56)(49)~(52)のいずれかに記載の組成物を哺乳動物に投与することを含む、ヒトT細胞白血病ウイルス1型(HTLV-1)感染を予防及び/又は治療する方法。
(57) (49)~(52)のいずれかの組成物を哺乳動物に投与することを含む、成人T細胞白血病・リンパ腫(ATLL)、HTLV-1関連脊髄症(HAM)及びHTLV-1ぶどう膜炎(HU)からなる群から選択されるHTLV-1に起因する疾患の発症を予防及び/又は治療する方法。
(58) ヒトT細胞白血病ウイルス1型(HTLV-1)のTax抗原であって、発がん性を低減又は消失させるような変異を有するTax抗原とシグナルペプチドを融合させたペプチド。
(59) Tax抗原が、配列番号11のアミノ酸配列に対して、T130A、L131S、L319R及びL320Sからなる群から選択される変異の少なくとも1つを有し、該変異アミノ酸以外のアミノ酸配列を比較した場合、配列番号11のアミノ酸配列と少なくとも95%の同一性を有するアミノ酸配列からなる(58)のペプチド。
(60) シグナルペプチドが配列番号13のアミノ酸配列の1番目~18番目のアミノ酸配列からなるペプチドである(58)又は(59)のペプチド。
(61) ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原を発現させることができる核酸が、キャップ構造(Cap)、5’非翻訳領域(5’-UTR)、gp46抗原又はTax抗原の翻訳領域及び3’非翻訳領域(3’-UTR)からなる構成を含むmRNAである(31)~(37)のいずれかに記載の粒子。
(62) キャップ構造(Cap)、5’非翻訳領域(5’-UTR)、gp46抗原又はTax抗原の翻訳領域及び3’非翻訳領域(3’-UTR)からなる構成が、配列番号17の1番目から1141番目の配列又は配列番号18の1番目から1222番目の配列と少なくとも90%の同一性を有するヌクレオチド配列である(61)に記載の粒子。
(63) キャップ構造(Cap)、5’非翻訳領域(5’-UTR)、gp46抗原又はTax抗原の翻訳領域及び3’非翻訳領域(3’-UTR)からなる構成が、配列番号20の1番目から1315番目の配列 と少なくとも90%の同一性を有するヌクレオチド配列である(61)に記載の粒子。
本明細書は本願の優先権の基礎となる日本国特許出願番号2021-084942号の開示内容を包含する。
R1及びR2は、独立して、C1-C3アルキル基を示し;
L1は、C2-C4アルカノイルオキシ基を1若しくは複数個有していてもよいC17-C19アルケニル基を示し;
L2は、C2-C4アルカノイルオキシ基を1若しくは複数個有していてもよいC10-C19アルキル基、又はC2-C4アルカノイルオキシ基を1若しくは複数個有していてもよいC10-C19アルケニル基を示し;
pは、3、又は4である。
SU gp46:HTLV-1のエンベロープタンパク質の細胞外領域(surface unit)であるgp46を表す。
gp46-Fib:gp46とFibritinのC末領域との融合タンパク質を表す。dgp62-Fib:gp62から膜貫通領域及び細胞内領域を欠損させたタンパク質とFibritinのC末領域との融合タンパク質を表す。
sec Tax mutant:変異導入Taxタンパク質と分泌シグナルタンパク質との融合タンパク質を表す。
(1)SU gp46のin vitro transcription(IVT)用の鋳型DNAの作製
In vitro transcription(IVT)に用いる鋳型DNAを作製するためにSU gp46 DNAをPCRにより増幅後精製した。T7プロモーター配列、human β-globinの5’-UTR配列、KOZAK配列、SU gp46、human β-globinの3’-UTR配列、PolyA配列が順に連結した配列を含むDNA断片(配列番号1)をプラスミドに導入した。当該プラスミド8ngを溶解したNuclease-free water(547.2 μL)に10×Buffer for KOD-Plus- Ver.2(80 μL、東洋紡(株) catalog # KOD-211)、2 mM dNTP mix(80 μL 、東洋紡(株) catalog # KOD-211)、25 mM MgSO4(48 μL、東洋紡(株) catalog # KOD-211)、50 μM センスプライマー(4.8 μL、配列番号2)、10 μM アンチセンスプライマー(24 μL、配列番号3)、KOD Plus polymerase(16μL、東洋紡(株) catalog # KOD-211)を加え、98℃で1分インキュベーション後、98℃、5秒、55℃、15秒、68℃、90秒を20サイクル実施し、更に68℃で1分インキュベートし、DNAを増幅した。反応後Wizard SV Gel and PCR Clean-Up System(Promega catalog # A9281)にて鋳型DNA(配列番号4)を精製した。
実施例1-(1)で得られた365.1 μg/mL 鋳型DNA(4.38 μL)、100 mM CleanCap AG(8 μL, TriLink catalog # N-7113)、100 mM ATP(8 μL, Hongene catalog # R1331)、100 mM GTP(8 μL, Hongene catalog # R2331)、100 mM CTP(8 μL, Hongene catalog # R3331)、100 mM N1-methylpseudoUTP(8 μL, Hongene catalog # R5-027)、Nuclease-free water(67.62 μL, Thermo Fisher catalog # AM9937)、T7 Transcription 5× buffer(32 μL, Promega catalog # P140X)、Enzyme mix, T7 RNA Polymerase(16 μL, Promega catalog # P137X)を混合し、37℃で4時間インキュベーションした。RQ1 RNase-Free DNase(8 μL, Promega catalog # M6101)を混合し、37℃で15分インキュベーションした。8 M LiCl溶液(80 μL, Sigma-Aldrich catalog # L7026)を混合し、-30℃で終夜静置した。遠心分離(4℃、5200×g、35分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、5200×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free water(500 μL)に溶解後、RNeasy Midi kit(Qiagen catalog # 75144)を用いて付属のマニュアル通りに精製した。得られた溶液(750 μL)、rApid Alkaline Phosphatase(Roche catalog # 04 898 141 001)の緩衝液(85 μL)と酵素(32 μL)を混合し、37℃で30分インキュベーション後、75℃で2分インキュベーションした。得られた溶液をRNeasy Midi kit(Qiagen catalog # 75144)を用いて付属のマニュアル通りに精製することで目的とするmRNAを得た。同様の実験操作を計2回行い、得られたmRNA溶液をまとめて、目的とするmRNAを得た。得られたmRNAは配列番号17の配列を有する。
(1)gp46-Fibのin vitro transcription(IVT)用の鋳型DNAの作製
In vitro transcription(IVT)に用いる鋳型DNAを作製するためにgp46-Fib DNAをPCRにより増幅後精製した。T7プロモーター配列、human β-globinの5’-UTR配列、KOZAK配列、gp46-Fib、human β-globinの3’-UTR配列、PolyA配列が順に連結した配列を含むDNA断片(配列番号5)をプラスミドに導入した。当該プラスミド8ngを溶解したNuclease-free water(547.2 μL)に10×Buffer for KOD-Plus- Ver.2(80 μL、東洋紡(株) catalog # KOD-211)、2 mM dNTP mix(80 μL 、東洋紡(株) catalog # KOD-211)、25 mM MgSO4(48 μL、東洋紡(株) catalog # KOD-211)、50 μM センスプライマー(4.8 μL、配列番号2)、10 μM アンチセンスプライマー(24 μL、配列番号3)、KOD Plus polymerase(16μL、東洋紡(株) catalog # KOD-211)を加え、98℃で1分インキュベーション後、98℃、5秒、55℃、15秒、68℃、90秒を20サイクル実施し、更に68℃で1分インキュベートし、DNAを増幅した。反応後Wizard SV Gel and PCR Clean-Up System(Promega catalog # A9281)にて鋳型DNA(配列番号6)を精製した。
実施例2-(1)で得られた345.3 μg/mL 鋳型DNA(4.63 μL)、100 mM CleanCap AG(8 μL, TriLink catalog # N-7113)、100 mM ATP(8 μL, Hongene catalog # R1331)、100 mM GTP(8 μL, Hongene catalog # R2331)、100 mM CTP(8 μL, Hongene catalog # R3331)、100 mM N1-methylpseudoUTP(8 μL, Hongene catalog # R5-027)、Nuclease-free water(67.37 μL, Thermo Fisher catalog # AM9937)、T7 Transcription 5× buffer(32 μL, Promega catalog # P140X)、Enzyme mix, T7 RNA Polymerase(16 μL, Promega catalog # P137X)を混合し、37℃で4時間インキュベーションした。RQ1 RNase-Free DNase(8 μL, Promega catalog # M6101)を混合し、37℃で15分インキュベーションした。8 M LiCl溶液(80 μL, Sigma-Aldrich catalog # L7026)を混合し、-30℃で終夜静置した。遠心分離(4℃、5200×g、35分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、5200×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free water(500 μL)に溶解後、RNeasy Midi kit(Qiagen catalog # 75144)を用いて付属のマニュアル通りに精製した。得られた溶液(750 μL)、rApid Alkaline Phosphatase(Roche catalog # 04 898 141 001)の緩衝液(85 μL)と酵素(32 μL)を混合し、37℃で30分インキュベーション後、75℃で2分インキュベーションした。得られた溶液をRNeasy Midi kit(Qiagen catalog # 75144)を用いて付属のマニュアル通りに精製することで目的とするmRNAを得た。同様の実験操作を計2回行い、得られたmRNA溶液をまとめて、目的とするmRNAを得た。得られたmRNAは配列番号18の配列を有する。
(1)dgp62-Fibのin vitro transcription(IVT)用の鋳型DNAの作製
In vitro transcription(IVT)に用いる鋳型DNAを作製するためにdgp62-Fib DNAをPCRにより増幅後精製した。T7プロモーター配列、human β-globinの5’-UTR配列、KOZAK配列、dgp62-Fib、human β-globinの3’-UTR配列、PolyA配列が順に連結した配列を含むDNA断片(配列番号7)をプラスミドに導入した。当該プラスミド8ngを溶解したNuclease-free water(547.2 μL)に10×Buffer for KOD-Plus- Ver.2(80 μL、東洋紡(株) catalog # KOD-211)、2 mM dNTP mix(80 μL 、東洋紡(株) catalog # KOD-211)、25 mM MgSO4(48 μL、東洋紡(株) catalog # KOD-211)、50 μM センスプライマー(4.8 μL、配列番号2)、10 μM アンチセンスプライマー(24 μL、配列番号3)、KOD Plus polymerase(16μL、東洋紡(株) catalog # KOD-211)を加え、98℃で1分インキュベーション後、98℃、5秒、55℃、15秒、68℃、90秒を20サイクル実施し、更に68℃で1分インキュベートし、DNAを増幅した。反応後Wizard SV Gel and PCR Clean-Up System(Promega catalog # A9281)にて鋳型DNA(配列番号8)を精製した。
実施例3-(1)で得られた366.7 μg/mL 鋳型DNA(4.36 μL)、100 mM CleanCap AG(8 μL, TriLink catalog # N-7113)、100 mM ATP(8 μL, Hongene catalog # R1331)、100 mM GTP(8 μL, Hongene catalog # R2331)、100 mM CTP(8 μL, Hongene catalog # R3331)、100 mM N1-methylpseudoUTP(8 μL, Hongene catalog # R5-027)、Nuclease-free water(67.64 μL, Thermo Fisher catalog # AM9937)、T7 Transcription 5× buffer(32 μL, Promega catalog # P140X)、Enzyme mix, T7 RNA Polymerase(16 μL, Promega catalog # P137X)を混合し、37℃で4時間インキュベーションした。RQ1 RNase-Free DNase(8 μL, Promega catalog # M6101)を混合し、37℃で15分インキュベーションした。8 M LiCl溶液(80 μL, Sigma-Aldrich catalog # L7026)を混合し、-30℃で終夜静置した。遠心分離(4℃、5200×g、35分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、5200×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free water(500 μL)に溶解後、RNeasy Midi kit(Qiagen catalog # 75144)を用いて付属のマニュアル通りに精製した。得られた溶液(750 μL)、rApid Alkaline Phosphatase(Roche catalog # 04 898 141 001)の緩衝液(85 μL)と酵素(32 μL)を混合し、37℃で30分インキュベーション後、75℃で2分インキュベーションした。得られた溶液をRNeasy Midi kit(Qiagen catalog # 75144)を用いて付属のマニュアル通りに精製することで目的とするmRNAを得た。同様の実験操作を計2回行い、得られたmRNA溶液をまとめて、目的とするmRNAを得た。得られたmRNAは配列番号19の配列を有する。
(1)sec Tax mutantのin vitro transcription(IVT)用の鋳型DNAの作製
In vitro transcription(IVT)に用いる鋳型DNAを作製するためにsec Tax DNAをPCRにより増幅後精製した。T7プロモーター配列、human β-globinの5’-UTR配列、KOZAK配列、sec Tax、human β-globinの3’-UTR配列、PolyA配列が順に連結した配列を含むDNA断片(配列番号9)をプラスミドに導入した。当該プラスミド8ngを溶解したNuclease-free water(547.2 μL)に10×Buffer for KOD-Plus- Ver.2(80 μL、東洋紡(株) catalog # KOD-211)、2 mM dNTP mix(80 μL 、東洋紡(株) catalog # KOD-211)、25 mM MgSO4(48 μL、東洋紡(株) catalog # KOD-211)、50 μM センスプライマー(4.8 μL、配列番号2)、10 μM アンチセンスプライマー(24 μL、配列番号3)、KOD Plus polymerase(16μL、東洋紡(株) catalog # KOD-211)を加え、98℃で1分インキュベーション後、98℃、5秒、55℃、15秒、68℃、90秒を20サイクル実施し、更に68℃で1分インキュベートし、DNAを増幅した。反応後Wizard SV Gel and PCR Clean-Up System(Promega catalog # A9281)にて鋳型DNA(配列番号10)を精製した。
実施例4-(1)で得られた401.1 μg/mL 鋳型DNA(3.99 μL)、100 mM CleanCap AG(8 μL, TriLink catalog # N-7113)、100 mM ATP(8 μL, Hongene catalog # R1331)、100 mM GTP(8 μL, Hongene catalog # R2331)、100 mM CTP(8 μL, Hongene catalog # R3331)、100 mM N1-methylpseudoUTP(8 μL, Hongene catalog # R5-027)、Nuclease-free water(68.01 μL, Thermo Fisher catalog # AM9937)、T7 Transcription 5× buffer(32 μL, Promega catalog # P140X)、Enzyme mix, T7 RNA Polymerase(16 μL, Promega catalog # P137X)を混合し、37℃で4時間インキュベーションした。RQ1 RNase-Free DNase(8 μL, Promega catalog # M6101)を混合し、37℃で15分インキュベーションした。8 M LiCl溶液(80 μL, Sigma-Aldrich catalog # L7026)を混合し、-30℃で終夜静置した。遠心分離(4℃、5200×g、35分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、5200×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free water(500 μL)に溶解後、RNeasy Midi kit(Qiagen catalog # 75144)を用いて付属のマニュアル通りに精製した。得られた溶液(750 μL)、rApid Alkaline Phosphatase(Roche catalog # 04 898 141 001)の緩衝液(85 μL)と酵素(32 μL)を混合し、37℃で30分インキュベーション後、75℃で2分インキュベーションした。得られた溶液をRNeasy Midi kit(Qiagen catalog # 75144)を用いて付属のマニュアル通りに精製することで目的とするmRNAを得た。同様の実験操作を計2回行い、得られたmRNA溶液をまとめて、目的とするmRNAを得た。得られたmRNAは配列番号20の配列を有する。
(1)SU gp46のin vitro transcription(IVT)用の鋳型DNAの作製
実施例1-(1)と同様の方法にて実施した。
実施例5-(1)で得られた339μg/mL 鋳型DNA(89μL)、100mM CleanCap AG(150μL,TriLink catalog # T-7113)、100mM ATP(150μL,Hongene catalog # R1331)、100mM GTP(150μL, Hongene catalog # R2331)、100mM CTP(150μL,Hongene catalog # R3331)、100mM N1-methyl-pseudouridine 5’-triphosphate(150μL,Hongene catalog # R5-027)、Nuclease-free water(1261μL,Qiagen catalog # 129114)、T7 Transcription 5× buffer(600μL,Promega catalog # P140X)、Enzyme mix,T7 RNA Polymerase(300μL,Promega catalog # P137X)を混合し、37℃で2時間インキュベーションした。RQ1 RNase-Free DNase(30μL, Promega catalog # M6101)を混合し、37℃で15分インキュベーションした。8M LiCl溶液(1500μL,Sigma-Aldrich catalog # L7026)を混合し、-20℃で終夜静置した。遠心分離(4℃、5250×g、30分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、5250×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free waterに溶解後、RNeasy Maxi kit(Qiagen catalog # 75162)を用いて付属のマニュアル通りに精製した。得られた溶出液(12mL、UV換算で12.0mg)とNuclease-free water(120μL)、rApid Alkaline Phosphatase(Roche catalog # 04 898 141 001)の緩衝液(1400μL)と酵素(480μL)を混合し、37℃で30分インキュベーションした。75℃で2分インキュベーションした後、8M LiCl溶液(7000μL,Sigma-Aldrich catalog # L7026)を混合し、-20℃で終夜静置した。遠心分離(4℃、5250×g、30分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、5250×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free water(2mL)に溶解した(UV換算で9.9mg)。得られたmRNAを逆相クロマトグラフィー(Column:PLRP-S,4000Å,10μm,10x200mm(Agilent)、Buffer A:5%アセトニトリル, 400mM酢酸トリエチルアミン(pH7.0)、Buffer B:25%アセトニトリル, 400mM酢酸トリエチルアミン(pH7.0)、Gradient B%:27.5%~35%(20min)、Flow rate:5mL/min、Temperature:80℃)にて分取精製した。目的の画分を回収し、限外ろ過(Amicon Ultra-15(MWCO:30kDa))により脱塩処理した(UV換算で3.4mg)。
(1)sec Tax mutantのin vitro transcription(IVT)用の鋳型DNAの作製
実施例4-(1)と同様の方法にて実施した。
実施例6-(1)で得られた336μg/mL 鋳型DNA(89μL)、100mM CleanCap AG(150μL,TriLink catalog # T-7113)、100mM ATP(150μL,Hongene catalog # R1331)、100mM GTP(150μL, Hongene catalog # R2331)、100mM CTP(150μL,Hongene catalog # R3331)、100mM N1-methyl-pseudouridine 5’-triphosphate(150μL,Hongene catalog # R5-027)、Nuclease-free water(1261μL,Qiagen catalog # 129114)、T7 Transcription 5× buffer(600μL,Promega catalog # P140X)、Enzyme mix,T7 RNA Polymerase(300μL,Promega catalog # P137X)を混合し、37℃で2時間インキュベーションした。RQ1 RNase-Free DNase(30μL, Promega catalog # M6101)を混合し、37℃で15分インキュベーションした。8M LiCl溶液(1500μL,Sigma-Aldrich catalog # L7026)を混合し、-20℃で終夜静置した。遠心分離(4℃、5250×g、30分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、5250×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free waterに溶解後、RNeasy Maxi kit(Qiagen catalog # 75162)を用いて付属のマニュアル通りに精製した。得られた溶出液(12mL、UV換算で12.6mg)とNuclease-free water(100μL)、rApid Alkaline Phosphatase(Roche catalog # 04 898 141 001)の緩衝液(1400μL)と酵素(500μL)を混合し、37℃で30分インキュベーションした。75℃で2分インキュベーションした後、8M LiCl溶液(7000μL,Sigma-Aldrich catalog # L7026)を混合し、-20℃で終夜静置した。遠心分離(4℃、5250×g、30分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、5250×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free water(2mL)に溶解した(UV換算で10.9mg)。得られたmRNAを逆相クロマトグラフィー(Column:PLRP-S,4000Å,10μm,10x200mm(Agilent)、Buffer A:5%アセトニトリル, 400mM酢酸トリエチルアミン(pH7.0)、Buffer B:25%アセトニトリル, 400mM酢酸トリエチルアミン(pH7.0)、Gradient B%:27.5%~35%(20min)、Flow rate:5mL/min、Temperature:80℃)にて分取精製した。目的の画分を回収し、限外ろ過(Amicon Ultra-15(MWCO:30kDa))により脱塩処理した(UV換算で3.7mg)。
(1)gp46-Fibのin vitro transcription(IVT)用の鋳型DNAの作製
実施例2-(1)と同様の方法にて実施した。
実施例7-(1)で得られた397μg/mL 鋳型DNA(63μL)、100mM CleanCap AG(50μL,TriLink catalog # T-7113)、100mM ATP(50μL,Hongene catalog # R1331)、100mM GTP(50μL, Hongene catalog # R2331)、100mM CTP(50μL,Hongene catalog # R3331)、100mM N1-methyl-pseudouridine 5’-triphosphate(50μL,Hongene catalog # R5-027)、Nuclease-free water(387μL,Qiagen catalog # 129114)、T7 Transcription 5× buffer(200μL,Promega catalog # P140X)、Enzyme mix,T7 RNA Polymerase(100μL,Promega catalog # P137X)を混合し、37℃で4時間インキュベーションした。RQ1 RNase-Free DNase(25μL, Promega catalog # M6101)を混合し、37℃で15分インキュベーションした。8M LiCl溶液(500μL,Sigma-Aldrich catalog # L7026)を混合し、-20℃で終夜静置した。遠心分離(4℃、5250×g、30分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、5250×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free waterに溶解後、RNeasy Maxi kit(Qiagen catalog # 75162)を用いて付属のマニュアル通りに精製した。得られた溶出液(3mL、UV換算で3.6mg)とNuclease-free water(332μL)、rApid Alkaline Phosphatase(Roche catalog # 04 898 141 001)の緩衝液(450μL)と酵素(718μL)を混合し、37℃で30分インキュベーションした。75℃で2分インキュベーションした後、RNeasy Maxi kitを用いて付属のマニュアル通りに精製することで目的とするmRNAを得た(4mL、UV換算で2.8mg)。
(1)sec Tax mutantのin vitro transcription(IVT)用の鋳型DNAの作製
実施例4-(1)と同様の方法にて実施した。
実施例8-(1)で得られた391μg/mL 鋳型DNA(64μL)、100mM CleanCap AG(50μL,TriLink catalog # T-7113)、100mM ATP(50μL,Hongene catalog # R1331)、100mM GTP(50μL, Hongene catalog # R2331)、100mM CTP(50μL,Hongene catalog # R3331)、100mM N1-methyl-pseudouridine 5’-triphosphate(50μL,Hongene catalog # R5-027)、Nuclease-free water(386μL,Qiagen catalog # 129114)、T7 Transcription 5× buffer(200μL,Promega catalog # P140X)、Enzyme mix,T7 RNA Polymerase(100μL,Promega catalog # P137X)を混合し、37℃で4時間インキュベーションした。RQ1 RNase-Free DNase(25μL, Promega catalog # M6101)を混合し、37℃で15分インキュベーションした。8M LiCl溶液(500μL,Sigma-Aldrich catalog # L7026)を混合し、-20℃で終夜静置した。遠心分離(4℃、5250×g、30分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、5250×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free waterに溶解後、RNeasy Maxi kit(Qiagen catalog # 75162)を用いて付属のマニュアル通りに精製した。得られた溶出液(3mL、UV換算で3.5mg)とNuclease-free water(359μL)、rApid Alkaline Phosphatase(Roche catalog # 04 898 141 001)の緩衝液(450μL)と酵素(691μL)を混合し、37℃で30分インキュベーションした。75℃で2分インキュベーションした後、RNeasy Maxi kitを用いて付属のマニュアル通りに精製することで目的とするmRNAを得た(4mL、UV換算で2.8mg)。
(1)mRNA封入核酸脂質粒子の調製
ジステアロイルホスファチジルコリン(1,2-Distearoyl-sn-glycero-3-phosphocholine:以下DSPCと表記,NOF CORPORATION)、コレステロール(Cholesterol:以下Cholと表記,Sigma-Aldrich,Inc.)、二酢酸(7R,9Z,26Z,29R)-18-({[3-(ジメチルアミノ)プロポキシ]カルボニル}オキシ)ペンタトリアコンタ-9,26-ジエン-7,29-ジイル(WO2015/005253の実施例23に記載の化合物)(以下LP1と表記)または酢酸(7R,9Z)-18-({[3-(ジメチルアミノ)プロピルオキシ]カルボニル}オキシ)オクタコサ-9-エン-7-イル(WO2015/005253の実施例28に記載の化合物)(以下LP2と表記)、及びポリエチレングリコール分子量が約2000の1、2-ジミリストイル-sn-グリセロール メトキシポリエチレン グリコール(1,2-Dimyristoyl-sn-Glycero-3-Methoxypolyethylene Glycol、以下PEG-DMGと表記,NOF CORPORATION,SUNBRIGHT GM-020)を、表1の記載のモル比にて、総脂質濃度5mMになるようにエタノールに溶解した。
(1)で調製した核酸脂質粒子を含む分散液の特性評価を行った。それぞれの特性評価の方法について説明する。
mRNAの封入率は、Quant-iT RiboGreen RNA Assay kit(Invitrogen)を用い、添付文書に準じて測定した。
すなわち、0.015% Triton X-100界面活性剤存在下及び非存在下において、核酸脂質粒子の分散液中のmRNAを定量し、次式により封入率を算出した。
{([界面活性剤存在下におけるmRNA量]-[界面活性剤非存在下におけるmRNA量])/[界面活性剤存在下におけるmRNA量]}x 100(%)
核酸脂質粒子の分散液中のmRNA量を下記のいずれかの方法にて測定した。
核酸脂質粒子分散液を1.0% Triton X-100にて希釈調製し、逆相クロマトグラフィーにて測定した(System:Agilent 1260series,Column:Bioshell A400 Protein C4(10cm×4.6mm,3.4μm)(SUPELCO),Buffer A:0.1M 酢酸トリエチルアミン(pH7.0),Buffer B:アセトニトリル,(B%):5-50%(0-15min),Flow Rate:1mL/min,Temperature:70℃,Detection:260nm)。
{[260nmにおける吸光度]-[350nmにおける吸光度]}x 40 x 希釈倍率(μg/mL)
[総脂質濃度]/[mRNA濃度] (wt/wt)
核酸脂質粒子の粒子径は、Zeta Potential/Particle Sizer NICOMPTM 380ZLS(PARTICLE SIZING SYSTEMS)にて測定した。表中の平均粒子径は体積平均粒子径を表し、±以下は、偏差を表す。
LTRレポーターアッセイ用のプラスミド構築
HTLV-1 Tax野生型(Uniprot Accession Number:P03409)、Tax変異型、及びTax変異型にIgE分泌シグナルを付加した分泌型Tax変異体をコードするDNAは、委託先であるEurofinで合成した。それぞれのDNA断片は、pcDNA3.1+ベクター(Thermo Scientific Inc.)のNheI/NotIサイトに挿入し、クローニングした。また、HIV-1 LTR及びHTLV-1 LTRをコードするDNAは、委託先であるEurofinで合成した。それぞれのDNA断片は、pGL4.17ベクター(Promega)のKpnI/XhoIサイトに挿入し、クローニングした。
350 ngのTax野生型、Tax変異型、又は分泌型Tax変異体を発現するプラスミド、100 ngのHIV-1 LTRレポータープラスミド又はHTLV-1 LTRレポータープラスミド、並びに50 ngのtransfection効率補正用のpRG-RKプラスミド(Promega)、合計500 ngのプラスミドを、HEK293T細胞にTransIT-LT1遺伝子導入試薬(Takara)を用いてtransfectionした。Transfectionから48時間後に、Dual-Glo(登録商標) Luciferase Assay System(Promega)を用いて、firefly luciferase発現量とRenilla luciferase発現量を測定し、firefly luciferase発現量/Renilla luciferase発現量の比を算出して、HIV-1 LTR及びHTLV-1 LTRの転写活性を評価した。
C3Hマウスへの実施例12の投与
C3H/HeJJclマウスは日本クレアから入手し馴化させた。2週間間隔で、麻酔下のマウスの消毒された下腿三頭筋へ実施例12を、5 μg mRNA/20 μL/mouseで投与した。初回は右脚へ、2回目は左脚へ投与した。脂質粒子の濃度調整および陰性対照群には、Bufferを用いた。
脂質粒子の初回投与から2週間後および2回目投与から1週間後に、麻酔下のマウスから採血を行った。血液は常温で1時間以上静置し、3000 RPMで10分間遠心して血清を分離し回収した。また、麻酔下で放血死させたマウスから脾臓を採取した。脾臓は、Cell Strainer(FALCON)のメッシュとシリンジ(TERUMO)のガスケットを使用してすり潰し、RPMI 1640(nacalai tesque)でsingle cell suspentionに調整した後、遠心にて細胞を回収した。上清を廃棄し、DB Pharm Lyse Lysing buffer(BECTON DICKINSON)を用いて赤血球の溶結処理を行った。遠心分離後RPMI 1640で再懸濁した細胞懸濁液をmini Cell Strainers(株式会社ハイテック、Cat.HT-AMS-14002)に通過させた。遠心分離後に上清を廃棄して細胞を再懸濁し、細胞濃度を測定した。遠心分離後に上清を廃棄して細胞培養液(RPMI 1640に10% Fetal Bovine Serum(非働化してフィルター通過、HyClone)、1% Penicillin-Streptomycin Mixed Solution(nacalai tesque)、1% Sodium Pyruvate(gibco)、1% MEM Non-Essential Amino Acids(gibco)、1% HEPES Buffer Solution(gibco)、1% StemSure Monothioglycerol Solution(FUJIFILM)を添加)で細胞濃度を調整した。なお、遠心は、1500 RPMで5分間、4℃で行った。
調整したマウス脾臓細胞3 x 106個を遠心して上清を廃棄した。1X Dulbecco’s Phosphate Buffered Saline(gibco)で細胞を再懸濁し、遠心して上清を廃棄する工程を2度繰り返した。その後、1X PBSで20倍希釈にしたTruStain FcX Antibody(BioLegend)を細胞に添加し、5分間常温で静置させた。5 μLのH-2DK HTLV-1 Tax38-46 Tetramer-ARLHTHALL-PE(MBL)を各サンプルに添加し、37℃、5%CO2で15分間インキュベートした。氷上にて、最終濃度が100倍希釈となるように調整したAPC/Fire(商標) 750 anti-mouse CD3 Antibody(BioLegend)とAnti-CD8(Mouse)mAb-FITC(MBL)をサンプルへと添加し、暗所で30分間静置した。遠心して上清を廃棄し、1X PBSで細胞を2度洗浄した。最後に細胞を400 μL PBSで再懸濁し、FACSVerse(BD)で標識された細胞を検出し、FlowJo(確認)で解析を行った。なお、遠心は、1500 RPMで5分間、4℃で行った。
Tax(MYBiosource)組み換えタンパク質を固相化抗原として使用するため、96ウェル平底プレートに添加し、4℃で一晩静置した。標準曲線希釈系列は、Mouse IgG(SouthernBiotech)を最高濃度0.25 μg/mLから3倍希釈で7段階作製した。各ウェルを洗浄し、ブロッキング溶液を添加して1時間常温にて静置した。血清サンプルは、ブロッキング溶液を用いて最高濃度の100倍希釈から4倍希釈で7段階作製した。ブロッキングしたプレートを洗浄し、希釈した試料をプレートへと添加して常温で1時間静置した。検出抗体、Goat Anti-Mouse IgG、Human ads-HRP(SouthernBiotech)、をブロッキング溶液で3000倍に希釈して、洗浄したウェルへと添加した。1時間後に洗浄して、TMB Microwell Peroxidase Substrate System(seracare)を添加して2~3分静置し、TMB Stop Solution(KPL、Cat.51500-0021)を用いて反応を停止した。プレートリーダーで、450 nmの吸光度から540 nmの吸光度を引いた補正吸光度を解析に使用し、抗gp46抗体価と抗Tax抗体価を算出した。なお、ブロッキング溶液は、1% Bovine Serum Albumin(Sigma)および0.05% Tween(BIO-RAD)を添加した1X Dulbecco’s Phosphate Buffered Saline(gibco)、洗浄は0.05%のTweenを添加した1X Dulbecco’s Phosphate Buffered Saline((10X) gibco)で3回行った。
カニクイザルへの投与
1回/2週、計4回、サルの上腕部に実施例13及び実施例14の脂質粒子を投与した。初回投与は右上腕部に投与し、その後は左右交互に投与した。脂質粒子投与量は、実施例13と実施例14のそれぞれを25 μg mRNAずつ等量混合し、1回あたり50 μg mRNA/200 μL/bodyを投与した。
サル血中抗gp46及びTax抗体価
組換えgp46タンパク質(RayBiotech)及び組み換えTaxタンパク質(MY Biosource)を96ウェルプレートに添加し、4℃で一晩固相化した。その後、プレートウォッシャーを用いて(0.05% Tween 20含有PBS洗浄液で3回)洗浄し、ブロッキング溶液(1% BSA、0.05% Tween 20含有PBS)を添加してブロッキングした。サル血漿試料希釈系列は、ブロッキング溶液を用いて最高濃度の100倍希釈血清から、4倍希釈で7段階作製した。サルIgG濃度の標準曲線希釈系列は、サルIgG溶液(メーカー)をブロッキング溶液で最高濃度の0.25 μg/mLから、3倍希釈で8段階作製した。試料希釈溶液及び標準曲線希釈溶液を添加し、室温で1時間静置後、プレートウォッシャーで洗浄した。検出抗体は、HRP標識抗サルIgG抗体(Sigma-Aldrich)をブロッキング溶液で4000倍希釈してプレートに添加後、室温で1時間静置した。プレートウォッシャーで洗浄した後、TMB Microwell Peroxidase Substrate System(SERACARE Life Sciences)を添加し、10分間静置した。反応停止液には、TMB Stop Solution(SERACARE Life Sciences)を用いた。プレートリーダーを用いて波長450 nm(対照波長540 nm)の吸光度を測定し、450 nmで測定した吸光度から540 nmで測定した吸光度を引いた補正吸光度(Delta)を解析に用いた。標準曲線のサルIgG濃度及びDeltaから、Nonlinear Regression:4 Parameterを用いて検量線を作成した。検量線、測定試料の希釈倍率、及びDeltaから試料の抗gp46及びTax抗体濃度を算出した。
サルにおけるgp46及びTax特異的細胞性免疫応答
サル末梢血からFicoll(Cytiva)を用いて分離したPBMCをRPMI Complete培地(10% FBS [Sigma-Aldrich]、1% PS [Penicilin-Streptomycin Mixed Solution、Nacalai Tesque]、1mM Sodium Pyruvate[Thermo Fisher Scientific]、10 mM HEPES[Thermo Fisher Scientific]、1×StemSure[富士フィルム和光純薬]、1×MEM Non-Essential Amino Acids Solution [Thermo Fisher Scientific])で2×106 cells/mLに調製し、IFN-γ ELISpot plate(MABTech)に100 μL/wellで播種した。その後、RPMI Complete培地で最終濃度0.1%(v/v)に調製したTaxエピトープペプチドプール(Eurofins)又は1 μg/mLに調製したgp46組み換えタンパク質(RayBiotech)を100 μL/wellで添加し、37℃、5% CO2の条件下で48時間培養した。抗原特異的IFN-γ産生細胞は、Monkey IFN-γ ELISpotPLUS kit (HRP)(MABTech)を用いて検出した。抗原特異的IFN-γ産生細胞数は、ELISPOTアナライザー(CTL)を用いて測定した。
サル血中抗HTLV-1中和活性
Spin column based Antibody Purification Kit(コスモバイオ)を用いて、4回目投与から2週後に採取・調製したサル血漿から、total IgGを精製した。HTLV-1感染細胞であるYT#1細胞株に精製IgGを添加し、次にHTLV-1非感染細胞株であるCEM細胞をYT#1細胞比一定1:1の割合で混合し、その共培養系に患者血清を添加してから一晩培養後の合胞体形成の有無率を測定検鏡した。
マウス血中gp46特異的total IgG抗体価
gp46(Ray Biotech Inc.)組み換えタンパク質を固相化抗原として使用するため、96ウェル平底プレートに添加し、4℃で一晩静置した。標準曲線希釈系列は、Mouse IgG(SouthernBiotech)を最高濃度0.25 μg/mLから3倍希釈で7段階作製した。各ウェルを洗浄し、ブロッキング溶液を添加して1時間常温にて静置した。血清サンプルは、ブロッキング溶液を用いて最高濃度の100倍希釈から4倍希釈で7段階作製した。ブロッキングしたプレートを洗浄し、希釈した試料をプレートへと添加して常温で1時間静置した。検出抗体、Goat Anti-Mouse IgG、Human ads-HRP(SouthernBiotech)、をブロッキング溶液で3000倍に希釈して、洗浄したウェルへと添加した。1時間後に洗浄して、TMB Microwell Peroxidase Substrate System(seracare)を添加して2~3分静置し、TMB Stop Solution(KPL、Cat.51500-0021)を用いて反応を停止した。プレートリーダーで、450 nmの吸光度から540 nmの吸光度を引いた補正吸光度を解析に使用し、抗gp46抗体価と抗Tax抗体価を算出した。なお、ブロッキング溶液は、1% Bovine Serum Albumin(Sigma)および0.05% Tween(BIO-RAD)を添加した1X Dulbecco’s Phosphate Buffered Saline(gibco)、洗浄は0.05%のTweenを添加した1X Dulbecco’s Phosphate Buffered Saline((10X)gibco)で3回行った。
マウスにおけるgp46及びTax特異的細胞性免疫応答
調整したマウス脾臓細胞106個/wellを96ウェルU底プレート(FALCON)に播種し、最終濃度が10 μg/mLとなるように調整したgp46およびTax pooled peptide(Eurofins)で37℃、5%CO2で刺激をした。24時間後に培養上清を回収し、IFN-γ(R&D Systems)とIL-2(R&D Systems)産生の測定をキットのプロトコールどおりに行った。
タンパク質発現解析
培養中のmRNA濃度が3 μg/mLとなるように、実施例9、10、11、12をCHO-S細胞(Thermo Fisher Scientific)に添加した。添加から72時間後に培養上清と細胞ペレットを回収した。細胞ペレットは、M-PER(商標) Tissue Protein Extraction Reagent(Thermo Scientific)を加えてVortexにてよく混合し、10分間常温にて静置させた。再度、Vortexして混合し、遠心分離後(3000 RPM、4℃、10分間)に細胞溶解液を回収した。培養上清中及び細胞溶解液中のgp46タンパク質は、Western blotting法を用いて検出した。
HIV-1 LTR及びHTLV-1 LTRの転写活性を指標としたTax抗原デザインの選抜
Tax野生型、Tax変異型、及び分泌型Tax変異体によるHIV-1 LTR転写活性及びHTLV-1 LTR転写活性を評価した(図1)。その結果、Tax野生型と比較して、Tax変異型はHIV-1 LTR転写活性及びHTLV-1 LTR転写活性の低下が認められた。また、分泌型Tax変異体は陰性コントロールと同等のHIV-1 LTR転写活性及びHTLV-1 LTR転写活性を示した。以上の結果から、HIV-1 LTR転写活性及びHTLV-1 LTR転写活性が最も低い分泌型Tax変異体は、がん原性が最も低いワクチン抗原候補であることが示唆された。
実施例12によるCTL誘導レベル及び血中抗Tax抗体価
実施例12を投与したC3HマウスにおけるCTL誘導レベルを評価した(図2)。その結果、実施例12によって、Tax特異的CTL及び血中抗Tax抗体応答が誘導された。
サル血中抗gp46及びTax抗体価
実施例13及び実施例14を等量混合した脂質粒子製剤によって誘導される血中抗gp46抗体応答及び血中抗Tax抗体応答を評価した(図3)。その結果、投与前(0W)と比較して、2回投与後(4W)及び3回投与後(6W)は、血中抗gp46抗体価及び抗Tax抗体価が高かった。
サルPBMC中のgp46及びTax特異的なIFN-γ産生細胞レベル
実施例13及び実施例14の混合製剤によって誘導される血中抗gp46抗体応答及び血中抗Tax抗体応答を評価した(図4)。4回目投与から7週後に採取・調製したPBMCを用いて検討した結果、実施例5及び実施例6の混合製剤群は、gp46特異的及びTax特異的なIFN-γ産生細胞の誘導が認められた。
サル血中抗HTLV-1中和活性
実施例13及び実施例14の混合製剤によって誘導される血中抗HTLV-1中和活性を評価した(図5)。4回目投与から2週後に採取・精製した血中total IgGを用いて検討した結果、陰性対照群と比較して、脂質粒子投与群の4頭中3頭で、血中抗HTLV-1中和活性が認められた。
マウス血中抗gp46抗体価
実施例9、実施例10、実施例11又は実施例12の脂質粒子の投与によって誘導される血中抗gp46抗体応答を評価した(図6)。その結果、陰性対照群と比較して、実施例9群、実施例10群、及び実施例11群では高い血中抗gp46抗体応答が認められた。
C57BL/6マウスにおけるgp46特異的及びTax特異的な細胞性免疫応答
実施例9、実施例10、実施例11、又は実施例12の脂質粒子の投与によって誘導されるgp46特異的及びIL-2特異的細胞性免疫をIFN-γ産生レベル及びIL-2産生レベルを指標として評価した(図7)。その結果、陰性対照群と比較して、実施例9群、実施例10群、及び実施例11群では、高いgp46特異的な細胞性免疫応答が認められた。また、陰性対照群と比較して、実施例12群では、高いTax特異的な細胞性免疫応答が認められた。
実施例9から実施例12の脂質粒子による抗原タンパク質の発現レベル
実施例9から実施例12で処理したCHO-S細胞の培養上清中及び細胞溶解液中の各脂質粒子が発現する抗原タンパク質の発現レベルを評価した(図8)。その結果、各脂質粒子が発現する抗gp46抗体が結合する抗原タンパク質の発現が認められた。なお、gp46タンパク質は、39 kDaである。
(1)gp46-Fibのin vitro transcription(IVT)用の鋳型DNAの作製
in vitro transcription(IVT)に用いる鋳型DNAを作製するためにプラスミドを構築した。T7プロモーター配列、human β-globinの5’-UTR配列、KOZAK配列、gp46-Fibの翻訳領域、human β-globinの3’-UTR配列及びpolyA配列が順に連結した配列を含むDNA断片(配列番号21~25)を導入したプラスミドを作製した(配列番号21~25のDNA断片を導入したプラスミドをそれぞれ用いて実施例25~29を実施した。)。
(1)で得られたプラスミド(300 μg)を溶解したNuclease-free water(268 μL)に10× NEBuffer 3.1、BspQI(32 μL、New England Biolabs catalog # R0712L)を加え、50℃で16時間インキュベーション後、80℃で20分インキュベーションした。エタノール(900 μL)、3 mol/L 酢酸ナトリウム溶液(30 μL)を混合し、-80℃で4時間静置した。遠心分離(4℃、15000×g、30分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、15000×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free water で500 μg/mLの溶液に調製した。
(2)で得られた500 μg/mL 鋳型DNA(15 μL)、100 mM CleanCap AG(15 μL, TriLink catalog # N-7113)、100 mM ATP(15 μL, Hongene catalog # R1331)、100 mM GTP(15 μL, Hongene catalog # R2331)、100 mM 5-Me-CTP(15 μL, Hongene catalog # R3-029)、100 mM 5-Me-UTP(15 μL, Hongene catalog # R5-104)、Nuclease-free water(113 μL)、5×IVT buffer (60 μL, 400 mM HEPES-KOH pH7.5, 400 mM DTT, 120 mM MgCl2, 10 mM Spermidine )、T7 RNA Polymerase(15 μL, Promega catalog # P407X)、RNase Inhibitor(15 μL,Promega catalog # P261X)、Pyrophosphatase(7.5 μL,Hongene catalog # ON-025)を混合し、37℃で4時間インキュベーションした。RQ1 RNase-Free DNase(7.5 μL, Promega catalog # M6101)を混合し、37℃で30分間インキュベーションした。10 M 酢酸アンモニウム溶液(100 μL,)を混合し、-20℃で2時間静置した。遠心分離(4℃、15000×g、30分)後、上澄みを廃棄、70%エタノールを加え、遠心分離(4℃、15000×g、10分)後、上澄みを廃棄し風乾した。得られた残渣をNuclease-free waterに溶解し、NucleoSpin(Macherey-Nagel catalog # 740948.50)にて精製し、目的とするmRNAを得た。
(1)mRNA封入核酸脂質粒子の調製
実施例1~8に記載のmRNAの代わりに実施例25~29で得られたmRNAをそれぞれ用いて実施例9~24と同様の方法にて、表3に記載の核酸脂質粒子を調製した。
実施例9~24と同様の方法にて、核酸脂質の特性評価を実施し、結果を表4に示した。
gp46タンパク質発現解析
培地中のmRNA濃度が3 μg/mLとなるように、実施例30~34をCHO-S細胞(Thermo Fisher Scientific)に添加した。また、陰性コントロールとして、実施例35~39の粒子の添加液量と等量のBufferを添加した。添加から3日後に培養上清を回収した。培養上清中のgp46タンパク質は、D-PBSで10倍に希釈した培養上清を96 half wellプレートに固相化し、実施例10を投与したマウスの血清を用いたEnzyme-Linked Immunosorbent Assay(ELISA)法によって検出した。
実施例30~34のgp46発現誘導能
実施例30~34で処理したCHO-S細胞の培養上清中のgp46タンパク質発現レベルを評価した。その結果、実施例30~34で処理したCHO-S細胞は、gp46タンパク質を発現した(図28)。
配列番号2:センスプライマーのヌクレオチド配列
配列番号3:アンチセンスプライマーのヌクレオチド配列
配列番号4:SU gp46のin vitro transcription(IVT)用の鋳型DNAのヌクレオチド配列
配列番号5:HTLV-I gp46-Fib IVT用の鋳型プラスミドDNAのヌクレオチド配列
配列番号6:gp46-Fibのin vitro transcription(IVT)用の鋳型DNAのヌクレオチド配列
配列番号7:HTLV-I dgp62-Fib IVT用の鋳型プラスミドDNAのヌクレオチド配列
配列番号8:dgp62-Fibのin vitro transcription(IVT)用の鋳型DNAのヌクレオチド配列
配列番号9:HTLV-I sec Tax mutant IVT用の鋳型プラスミドDNAのヌクレオチド配列
配列番号10:sec Tax mutantのin vitro transcription(IVT)用の鋳型DNAのヌクレオチド配列
配列番号11:Tax野生型のアミノ酸配列
配列番号12:Tax変異型(T130A/L131S/L319R/L320S)のアミノ酸配列
配列番号13:分泌型Tax変異体(T130A/L131S/L319R/L320S)のアミノ酸配列
配列番号14:gp46のアミノ酸配列
配列番号15:gp46-Fibのアミノ酸配列
配列番号16:dgp62-Fibのアミノ酸配列
配列番号17:SU gp46 mRNA
配列番号18:gp46-Fib mRNA
配列番号19:dgp62-Fib mRNA
配列番号20:sec Tax mutant mRNA
配列番号21:gp46-Fibの鋳型DNAのヌクレオチド配列 polyA95
配列番号22:gp46-Fibの鋳型DNAのヌクレオチド配列 polyA80
配列番号23:gp46-Fibの鋳型DNAのヌクレオチド配列 polyA60
配列番号24:gp46-Fibの鋳型DNAのヌクレオチド配列 polyA40
配列番号25:gp46-Fibの鋳型DNAのヌクレオチド配列 polyA20
配列番号26:sec Tax mutantの鋳型DNAのヌクレオチド配列 polyA95
配列番号27:sec Tax mutantの鋳型DNAのヌクレオチド配列 polyA80
配列番号28:sec Tax mutantの鋳型DNAのヌクレオチド配列 polyA60
配列番号29:sec Tax mutantの鋳型DNAのヌクレオチド配列 polyA40
配列番号30:sec Tax mutantの鋳型DNAのヌクレオチド配列 polyA20
配列番号31:gp46-FibのmRNA配列 polyA95
配列番号32:gp46-FibのmRNA配列 polyA80
配列番号33:gp46-FibのmRNA配列 polyA60
配列番号34:gp46-FibのmRNA配列 polyA40
配列番号35:gp46-FibのmRNA配列 polyA20
配列番号36:sec Tax mutantのmRNA配列 polyA95
配列番号37:sec Tax mutantのmRNA配列 polyA80
配列番号38:sec Tax mutantのmRNA配列 polyA60
配列番号39:sec Tax mutantのmRNA配列 polyA40
配列番号40:sec Tax mutantのmRNA配列 polyA20
本明細書で引用した全ての刊行物、特許及び特許出願はそのまま引用により本明細書に組み入れられるものとする。
Claims (57)
- ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原を発現させることができる核酸を封入した脂質粒子であって、脂質が一般式(Ia)で表されるカチオン性脂質、又はその薬学的に許容される塩を含む前記粒子。
R1及びR2は、独立して、C1-C3アルキル基を示し;
L1は、C2-C4アルカノイルオキシ基を1若しくは複数個有していてもよいC17-C19アルケニル基を示し;
L2は、C2-C4アルカノイルオキシ基を1若しくは複数個有していてもよいC10-C19アルキル基、又はC2-C4アルカノイルオキシ基を1若しくは複数個有していてもよいC10-C19アルケニル基を示し;
pは、3、又は4である。 - 一般式(Ia)中のR1及びR2が、共にメチル基である、請求項1に記載の粒子。
- 一般式(Ia)中のpが、3である請求項1又は2に記載の粒子。
- 一般式(Ia)中のL1が、アセトキシ基を1若しくは複数個有していてもよいC17-C19アルケニル基である、請求項1~3のいずれか1項に記載の粒子。
- 一般式(Ia)中のL2が、アセトキシ基を1若しくは複数個有していてもよいC10-C12アルキル基、又はアセトキシ基を1若しくは複数個有していてもよいC10-C19アルケニル基である、請求項1~4のいずれか1項に記載の粒子。
- 一般式(Ia)中のL2が、アセトキシ基を1若しくは複数個有していてもよいC10-C12アルキル基、又はアセトキシ基を1若しくは複数個有していてもよいC17-C19アルケニル基である、請求項1~4のいずれか1項に記載の粒子。
- 一般式(Ia)中のL1が、(R)-11-アセチルオキシ-cis-8-ヘプタデセニル基、cis-8-ヘプタデセニル基、又は(8Z,11Z)-ヘプタデカジエニル基である請求項1~6のいずれか1項に記載の粒子。
- 一般式(Ia)中のL2が、デシル基、cis-7-デセニル基、ドデシル基、又は(R)-11-アセチルオキシ-cis-8-ヘプタデセニル基である、請求項1~7のいずれか1項に記載の粒子。
- 脂質が、さらに、両親媒性脂質、ステロール類及びPEG脂質を含む請求項9又は10に記載の粒子。
- 脂質が、さらに、両親媒性脂質、ステロール類及びPEG脂質を含む請求項11に記載の粒子。
- 両親媒性脂質が、ジステアロイルホスファチジルコリン、ジオレオイルホスファチジルコリン及びジオレオイルホスファチジルエタノールアミンからなる群より選択される少なくとも1つである請求項12に記載の粒子。
- 両親媒性脂質が、ジステアロイルホスファチジルコリン、ジオレオイルホスファチジルコリン及びジオレオイルホスファチジルエタノールアミンからなる群より選択される少なくとも1つである請求項13に記載の粒子。
- ステロール類がコレステロールである請求項12又は14に記載の粒子。
- ステロール類がコレステロールである請求項13又は15に記載の粒子。
- PEG脂質が、1,2-ジミリストイル-sn-グリセロール メトキシポリエチレン グリコール及び/又はN-[メトキシ ポリ(エチレングリコール)2000]カルバモイル]-1,2-ジミリスチルオキシプロピル-3-アミンである請求項12、14、16のいずれか1項に記載の粒子。
- PEG脂質が、1,2-ジミリストイル-sn-グリセロール メトキシポリエチレン グリコール及び/又はN-[メトキシ ポリ(エチレングリコール)2000]カルバモイル]-1,2-ジミリスチルオキシプロピル-3-アミンである請求項13、15、17のいずれか1項に記載の粒子。
- 両親媒性脂質、ステロール類、カチオン性脂質、及びPEG脂質の脂質組成が、モル量にて、両親媒性脂質が5~25%、ステロール類が10~55%、カチオン性脂質が40~65%、PEG脂質が1~5%である請求項12~19のいずれか1項に記載の粒子。
- 両親媒性脂質が10~25%である請求項20に記載の粒子。
- 両親媒性脂質、ステロール類、カチオン性脂質、及びPEG脂質の脂質組成が、モル量にて、両親媒性脂質が5~15%、ステロール類が35~50%、カチオン性脂質が40~55%、PEG脂質が1~3%である請求項12、14、16、18のいずれか1項に記載の粒子。
- 両親媒性脂質が10~15%、ステロール類が35~45%、カチオン性脂質が40~50%、PEG脂質が1~2.5%である請求項22に記載の粒子。
- PEG脂質が1~2%である請求項23に記載の粒子。
- 両親媒性脂質、ステロール類、カチオン性脂質、及びPEG脂質の脂質組成が、モル量にて、両親媒性脂質が10~25%、ステロール類が10~50%、カチオン性脂質が40~65%、PEG脂質が1~3%である請求項13、15、17、19のいずれか1項に記載の粒子。
- ステロール類が10~45%、カチオン性脂質が42.5~65%、PEG脂質が1~2.5%である請求項25に記載の粒子。
- PEG脂質が1~2%である請求項26に記載の粒子。
- 核酸重量に対する総脂質重量の比率が15~30である請求項20~27のいずれか1項に記載の粒子。
- 核酸重量に対する総脂質重量の比率が15~25である請求項28に記載の粒子。
- 核酸重量に対する総脂質重量の比率が17.5~22.5である請求項29に記載の粒子。
- ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原がオリゴマー化ドメインとの融合タンパク質である請求項1~30のいずれか1項に記載の粒子。
- オリゴマー化ドメインがフィブリチンである請求項31に記載の粒子。
- ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原が配列番号14のアミノ酸配列と少なくとも95%の同一性を有するアミノ酸配列からなる請求項31又は32に記載の粒子。
- ヒトT細胞白血病ウイルス1型(HTLV-1)のTax抗原が、配列番号11のアミノ酸配列に対して、T130A、L131S、L319R及びL320Sからなる群から選択される変異の少なくとも1つを有し、該変異アミノ酸以外のアミノ酸配列を比較した場合、配列番号11のアミノ酸配列と少なくとも95%の同一性を有するアミノ酸配列からなる請求項1~33のいずれか1項に記載の粒子。
- ヒトT細胞白血病ウイルス1型(HTLV-1)のTax抗原が、配列番号11のアミノ酸配列に対して、T130A、L131S、L319R及びL320Sの変異を有し、該変異アミノ酸以外のアミノ酸配列を比較した場合、配列番号11のアミノ酸配列と少なくとも95%の同一性を有するアミノ酸配列からなる請求項34に記載の粒子。
- ヒトT細胞白血病ウイルス1型(HTLV-1)のTax抗原が、シグナルペプチドとの融合タンパク質である請求項1~35のいずれか1項に記載の粒子。
- シグナルペプチドが配列番号13のアミノ酸配列の1番目~18番目のアミノ酸配列からなるペプチドである請求項36に記載の粒子。
- ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原を発現させることができる核酸が、キャップ構造(Cap)、5’非翻訳領域(5’-UTR)gp46抗原又はTax抗原の翻訳領域、3’非翻訳領域(3’-UTR)及びポリA尾部(polyA)を含むmRNAである請求項31~37のいずれか1項に記載の粒子。
- ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原を発現させることができる核酸の配列が、配列番号17又は18の配列と少なくとも90%の同一性を有するヌクレオチド配列からなる請求項38に記載の粒子。
- ヒトT細胞白血病ウイルス1型(HTLV-1)のTax抗原を発現させることができる核酸の配列が、配列番号20の配列と少なくとも90%の同一性を有するヌクレオチド配列からなる請求項38に記載の粒子。
- 核酸が少なくとも1個の修飾ヌクレオチドを含む請求項1~40のいずれか1項に記載の粒子。
- 修飾ヌクレオチドが、5位が置換したピリミジンヌクレオチド及び/又は1位が置換していてもよいシュードウリジンの少なくとも1個を含む請求項41に記載の粒子。
- 修飾ヌクレオチドが、5-メチルシチジン、5-メトキシウリジン、5-メチルウリジン、シュードウリジン、及び1-アルキルシュードウリジンからなる群から選ばれる少なくとも1個を含む請求項41に記載の粒子。
- 修飾ヌクレオチドが、5-メチルシチジン、5-メチルウリジン、及び1-メチルシュードウリジンからなる群から選ばれる少なくとも1個を含む請求項41に記載の粒子。
- 平均粒子径が30~300nmである請求項1~44のいずれか1項に記載の粒子。
- ヒトT細胞白血病ウイルス1型(HTLV-1)による感染を予防及び/又は治療するための組成物を製造するための請求項1~45のいずれか1項に記載の粒子の使用。
- 請求項1~45のいずれか1項に記載の粒子を含有する、組成物。
- ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原をin vivo又はin vitroで発現させるための請求項47に記載の組成物。
- 医薬として用いられる請求項47又は48に記載の組成物。
- ヒトT細胞白血病ウイルス1型(HTLV-1)に対する免疫反応を誘導するための請求項49に記載の組成物。
- ヒトT細胞白血病ウイルス1型(HTLV-1)感染を予防及び/又は治療するための請求項49又は50に記載の組成物。
- HTLV-1感染者に対して、成人T細胞白血病・リンパ腫(ATLL)、HTLV-1関連脊髄症(HAM)及びHTLV-1ぶどう膜炎(HU)からなる群から選択されるHTLV-1に起因する疾患の発症の予防及び/又は治療するための請求項49又は50に記載の組成物。
- 請求項47~50のいずれか1項に記載の組成物を細胞に導入することを含む、ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原をin vitroで発現させる方法。
- 請求項47~51のいずれか1項に記載の組成物を哺乳動物に投与することを含む、ヒトT細胞白血病ウイルス1型(HTLV-1)のgp46抗原又はTax抗原をin vivoで発現させる方法。
- 請求項49又は50に記載の組成物を哺乳動物に投与することを含む、ヒトT細胞白血病ウイルス1型(HTLV-1)に対する免疫反応を誘導する方法。
- 請求項49~52のいずれか1項に記載の組成物を哺乳動物に投与することを含む、ヒトT細胞白血病ウイルス1型(HTLV-1)感染を予防及び/又は治療する方法。
- 請求項49~52のいずれか1項に記載の組成物を哺乳動物に投与することを含む、成人T細胞白血病・リンパ腫(ATLL)、HTLV-1関連脊髄症(HAM)及びHTLV-1ぶどう膜炎(HU)からなる群から選択されるHTLV-1に起因する疾患の発症を予防及び/又は治療する方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280035124.6A CN117320746A (zh) | 2021-05-19 | 2022-05-18 | Htlv-1核酸脂质颗粒疫苗 |
JP2023522694A JPWO2022244801A1 (ja) | 2021-05-19 | 2022-05-18 | |
KR1020237039413A KR20240009944A (ko) | 2021-05-19 | 2022-05-18 | Htlv-1 핵산 지질 입자 백신 |
EP22804712.2A EP4342491A1 (en) | 2021-05-19 | 2022-05-18 | Htlv-1 nucleic acid lipid particle vaccine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-084942 | 2021-05-19 | ||
JP2021084942 | 2021-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022244801A1 true WO2022244801A1 (ja) | 2022-11-24 |
Family
ID=84141637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/020646 WO2022244801A1 (ja) | 2021-05-19 | 2022-05-18 | Htlv-1核酸脂質粒子ワクチン |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4342491A1 (ja) |
JP (1) | JPWO2022244801A1 (ja) |
KR (1) | KR20240009944A (ja) |
CN (1) | CN117320746A (ja) |
TW (1) | TW202313102A (ja) |
WO (1) | WO2022244801A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010508014A (ja) * | 2006-10-31 | 2010-03-18 | キュアバック ゲーエムベーハー | タンパク質の発現を増加させるための塩基修飾されたrna |
WO2015005253A1 (ja) | 2013-07-08 | 2015-01-15 | 第一三共株式会社 | 新規脂質 |
WO2015164674A1 (en) | 2014-04-23 | 2015-10-29 | Moderna Therapeutics, Inc. | Nucleic acid vaccines |
JP2021084942A (ja) | 2019-11-26 | 2021-06-03 | 三菱エンジニアリングプラスチックス株式会社 | ポリカーボネート樹脂組成物及び成形品 |
-
2022
- 2022-05-18 KR KR1020237039413A patent/KR20240009944A/ko unknown
- 2022-05-18 EP EP22804712.2A patent/EP4342491A1/en active Pending
- 2022-05-18 WO PCT/JP2022/020646 patent/WO2022244801A1/ja active Application Filing
- 2022-05-18 CN CN202280035124.6A patent/CN117320746A/zh active Pending
- 2022-05-18 TW TW111118482A patent/TW202313102A/zh unknown
- 2022-05-18 JP JP2023522694A patent/JPWO2022244801A1/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010508014A (ja) * | 2006-10-31 | 2010-03-18 | キュアバック ゲーエムベーハー | タンパク質の発現を増加させるための塩基修飾されたrna |
WO2015005253A1 (ja) | 2013-07-08 | 2015-01-15 | 第一三共株式会社 | 新規脂質 |
WO2015164674A1 (en) | 2014-04-23 | 2015-10-29 | Moderna Therapeutics, Inc. | Nucleic acid vaccines |
JP2021084942A (ja) | 2019-11-26 | 2021-06-03 | 三菱エンジニアリングプラスチックス株式会社 | ポリカーボネート樹脂組成物及び成形品 |
Non-Patent Citations (22)
Title |
---|
"2003 collection of research reports on a particular field (cancer-specific) related to cancer research", 1 January 2004, INSTITUTE OF MOLECULAR AND CELLULAR BIOLOGY, UNIVERSITY OF TOKYO , JP, article TAKASHI OHASHI: "Development of immunotherapy for human adult T-cell leukemia using rat models", pages: 129 - 131, XP009542710 * |
"Uniprot", Database accession no. P03409 |
BLOOD, vol. 119, no. 10, 2012, pages 2409 - 2416 |
CANCER RESEARCH, vol. 70, no. 15, 2010, pages 6181 - 6192 |
FRONT MICROBIOL., vol. 3, 2012, pages 406 |
GENE DEV., vol. 4, 1990, pages 1875 |
GIBSON D. G. ET AL., SCIENCE, vol. 319, no. 5867, 2008, pages 1215 - 1220 |
HASEGAWA, HIDEKI ET AL.: "Analysis of anti-HTLV antibody response in breast milk of vaccinated mother mice", SCIENTIFIC RESEARCH GRANTS OF THE MINISTRY OF HEALTH, LABOR, AND WELFARE OF JAPAN. EMERGING AND RE-EMERGING INFECTIOUS DISEASE RESEARCH PROJECT SUCH AS NEW STRAINS OF INFLUENZA. RESEARCH ON THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR HTLV-A INFECTI, 1 January 2013 (2013-01-01), pages 11 - 15, XP009542646 * |
J. BIOCHEM., vol. 150, no. 6, 2011, pages 679 - 686 |
J. BIOL CHEM., vol. 281, no. 19, 2006, pages 13075 - 13082 |
J. BIOL. CHEM., vol. 266, 1991, pages 12127 |
J. BIOL. CHEM., vol. 267, 1992, pages 16396 |
KABIRI MONA, SANKIAN MOJTABA, HOSSEINPOUR MITRA, TAFAGHODI MOHSEN: "The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 549, no. 1-2, 1 October 2018 (2018-10-01), NL , pages 404 - 414, XP093006331, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2018.07.069 * |
KORMANN, M., NATURE BIOTECHNOLOGY, vol. 29, 2011, pages 154 - 157 |
LANCET INFECT DIS, vol. 7, 2007, pages 266 - 281 |
OHASHI T, ET AL.: "Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type I Tax-coding DNA vaccine.", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 20, 1 October 2000 (2000-10-01), US , pages 9610 - 9616, XP002467099, ISSN: 0022-538X, DOI: 10.1128/JVI.74.20.9610-9616.2000 * |
OHASHI, TAKASHI ET AL.: "1-C-131-P/O Analysis of cytotoxicity for HTLV-I infected cells of CTL lines induced from rats vaccinated with Tax-expressing DNA", PROCEEDINGS OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, NIHON MEN'EKI GAKKAI // JAPANESE SOCIETY FOR IMMUNOLOGY (JSI), JP, vol. 30, 1 January 2000 (2000-01-01) - 16 November 2000 (2000-11-16), JP , pages 57, XP009541316, ISSN: 0919-1984 * |
RASHTCHIAN, A., CURRENT OPINION IN BIOTECHNOLOGY, vol. 6, 1995, pages 30 - 36 |
SAMBROOK, J. ET AL.: "Molecular Cloning a Laboratory Manual", 1989 |
SCIENCE, vol. 371, 2021, pages 1152 |
VIRUSES, vol. 3, no. 6, 2011, pages 714 - 749 |
VIRUSES, vol. 8, no. 2, 2016, pages 41 |
Also Published As
Publication number | Publication date |
---|---|
CN117320746A (zh) | 2023-12-29 |
JPWO2022244801A1 (ja) | 2022-11-24 |
EP4342491A1 (en) | 2024-03-27 |
TW202313102A (zh) | 2023-04-01 |
KR20240009944A (ko) | 2024-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20220140528A (ko) | Sars-cov-2 mrna 도메인 백신 | |
JP2024503698A (ja) | 変異型株ベースのコロナウイルスワクチン | |
JP2024514183A (ja) | エプスタイン-バーウイルスmRNAワクチン | |
WO2021163222A1 (en) | Rapid vaccine platform | |
CN116157148A (zh) | 免疫原性组合物及其用途 | |
WO2023147092A9 (en) | Coronavirus vaccine | |
US20240026317A1 (en) | PAN-RAS mRNA CANCER VACCINES | |
KR20180127402A (ko) | 사이클릭 디뉴클레오타이드를 포함하는 바이러스 입자의 제조 방법 및 암 치료를 위한 상기 입자의 용도 | |
WO2021251453A1 (ja) | 核酸脂質粒子ワクチン | |
WO2022244801A1 (ja) | Htlv-1核酸脂質粒子ワクチン | |
WO2021095838A1 (ja) | HPV mRNAを封入した核酸脂質粒子ワクチン | |
JPWO2007023725A1 (ja) | 遺伝子ワクチン | |
TW202330922A (zh) | 核糖核酸呼吸道融合病毒(rsv)疫苗之組合物及方法 | |
JPWO2022244801A5 (ja) | ||
WO2022244825A1 (ja) | インフルエンザウイルス核酸脂質粒子ワクチン | |
WO2022244815A1 (ja) | Hpv感染症ワクチン | |
TW202413424A (zh) | 免疫調節蛋白及相關方法 | |
WO2024073005A2 (en) | Exosome display compositions | |
CA3222139A1 (en) | Multiplexed tp53 and pan-ras mrna cancer vaccines | |
CN115724920A (zh) | 冠状病毒和流感病毒的二联核酸疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22804712 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2023522694 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18562059 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022804712 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022804712 Country of ref document: EP Effective date: 20231219 |